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I Introduction 
I.1 Dendritic cells 
Dendritic cells (DCs) are professional antigen presenting cells (APCs) of hematopoietic 
origin, which are specialized for the capture, processing and presentation of antigens (Ags) 
to T cells (Shortman and Naik 2007). At an immature stage of development, DCs act as 
sentinals in peripheral tissues, continuously sampling the environment. After Ag uptake, 
the Ag is processed and fixed on the DC surface as peptides, presented by major 
histocompatibility complex (MHC) molecules. Two types of these peptide-binding proteins 
exist: MHC class I and MHC class II. While intracellular Ags bind to MHC class I 
molecules and are recognized by CD8+ T cells, extracellular Ags are presented by MHC 
class II molecules to CD4+ T cells. Along with this peptide presentation on the surface, 
DCs upregulate co-stimulatory molecules that are required for effective interaction with T 
cells and migrate into peripheral lymphoid organs as the lymph nodes (LNs). Here, the 
now-mature DCs efficiently trigger a T cell mediated immune response by stimulating a T 
cell receptor that is specific for the foreign-peptide–MHC complexes on the DC surface 
(Fig. I.1) (Banchereau and Steinman 1998; Shortman and Liu 2002). 
 
Fig. I.1: Life cycle and function of DCs. Ags are captured by DCs in peripheral tissues and processed to 
form MHC–peptide complexes. As a consequence of Ag deposition and inflammation, DCs begin to mature, 
expressing molecules that will lead to binding and stimulation of T cells in the T cell areas of lymphoid 
tissues (Banchereau and Steinman 1998). 
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DC subsets 
The interaction of DCs with naïve T cells can lead to different forms of immune responses, 
or to T cell tolerance, depending on the type of DC and its activation state (Shortman and 
Naik 2007). Currently there is a controversial discussion concerning the adequate 
classification of the different DC subtypes, which is further complicated by the fact that 
there are main differences in terms of DC surface markers and functions in the human 
system compared with the mouse system. Distinct subtypes were initially more evident 
among mouse DCs than among human DCs, because of the availability of different murine 
lymphoid tissues and the expression of surface markers on mouse DCs that are not present 
on human DCs (Shortman and Liu 2002; Shortman and Naik 2007). Mouse DCs include 
myeloid and lymphoid DCs (so called conventional DCs (cDCs)) and plasmacytoid DCs 
(pDCs) in the circulation, and in lymphoid and nonlymphoid tissues. The resident cDCs in 
lymphoid tissues include cDCs present in the thymus, spleen, and LNs, furthermore consist 
of phenotypically different subtypes, which can be divided into subsets according to their 
tissue localizations (Geissmann, Prost et al. 1998; Serbina, Salazar-Mather et al. 2003; 
Steinman 2003; Naik, Metcalf et al. 2006; Randolph, Ochando et al. 2008). As such, five 
populations of LN DC have been described in the mouse (Henri, Vremec et al. 2001): 
1. CD4-CD8-CD11b+ myeloid DC 
2. CD4+CD8-CD11b+ myeloid DC 
3. CD8+CD11b- lymphoid DC 
4. CD8lowDEC-205low langerin expressing DC 
5. CD11intI-A+B220+Gr-1+ pDC 
In addition to their different tissue localization, DC subtypes are also divided into subsets 
according to their maturation status. In mouse, DCs that are classified as `mature´ express 
CD11c (the integrin-αx chain) and the co-stimulatory molecules CD80, CD86 and CD40, 
and have moderate to high surface levels of MHC-II molecules (Shortman and Liu 2002). 
The different DC subsets can readily be prepared from progenitors in vitro. For 
example, bone-marrow derived precursors (BMDP) isolated from mice and stimulated with 
cytokines, different growth factors and granulocyte–macrophage colony stimulating factor 
2
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(GM-CSF) lead to reasonable numbers of mature potent myeloid DCs (Inaba, Inaba et al. 
1992; Hieronymus, Gust et al. 2005). 
Features of mature DCs 
Mature DCs have many features of primary DCs, including the expression of molecules 
that enhance Ag capture and selective receptors that guide DCs to and from several sites in 
the body (Fig. I.2). No other blood cell exhibits the shape and motility that give rise to the 
term ‘dendritic’ cell. In situ, as in the skin, airways and lymphoid organs, DCs are stellate. 
When alive and viewed by phase-contrast microscopy, they present large, delicate 
protrusions, called dendrites, in many directions from the cell body. Based on in vivo 
studies that directly observed the DCs in the LNs, it has been suggested that these 
dendrites, by enhancing the net surface of the DCs, confer these cells with a high capability 
to “capture” T cells in the LNs and therefore increase their Ag-presenting ability 
(Kobayashi, Shinohara et al. 2001; Mempel, Moser et al. 2003). The shape and motility of 
DCs thus perfectly fit their functions, which are to mediate different T subset responses 
and other cell type-mediated antigenic responses, produce distinct cytokines, present auto-
Ags through their ability to internalize apoptotic cells and migrate in response to 
chemokines (Winzler, Rovere et al. 1997; Banchereau and Steinman 1998; Penna, Vulcano 
et al. 2002; Steinman 2003). 
 
 
Fig I.2: Some features of DCs: Many monoclonals to Ags that are not rigorously DC-specific, nor well 
understood, are still useful in identifying DCs. These are CD83, an immunoglobulin-superfamily member; 
p55, a presumptive actin-bundling protein; S100b, a calcium-binding cytosolic protein; DEC-205, a 
multilectin in DCs and many epithelia; antibodies called M342, 2A1 and MIDC-8 which recognize antigens 
in intracellular granules of mouse DCs; and OX62 on rat DCs and some T cells (Banchereau and Steinman 
1998). 
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I.2 T helper (Th) cells 
So far, three different effector Th cells are known, which all express CD4, but display 
distinct cytokine-secretion phenotypes eliciting unique functional characteristics. These 
cells are referred to as Th type-1 (Th1), Th type-2 (Th2) or Th type-17 (Th17) cells, 
depending on their phenotype. Differentiation of naïve Th cells (Th0) into Th1, Th2 or 
Th17 effector cells occurs within a few days of direct contact with APCs (Lafaille 1998). A 
number of factors are involved in determining the nature of the effector phenotype that 
develops, including the nature and affinity of the Ag, the type of T cell receptor (TCR) 
signaling, the nature of the coreceptor signals that are involved and, most importantly, the 
predominant cytokine environment. Th1 cells mediate a cellular immune response while 
Th2 cells potentiate a humoral response. Th17 cells appear to play an integral role in both 
tissue inflammation and activation of neutrophils to combat extracellular bacteria. Th1, 
Th2 and Th17 populations, and the cytokines they release, are antagonistic to each other 
and one or the other subtype is dominant in response to a particular pathogen at any time 
(Kaiko, Horvat et al. 2008). 
Th1 cell polarization 
Th1 cells secrete the cytokines interferon (IFN)-γ, and tumor necrosis factor (TNF)-β, 
which allow these cells to be particularly effective in protecting against intracellular 
infections by viruses and bacteria and micro-organisms that grow in macrophages (Kidd 
2003). Th1 cell development begins with the secretion of interleukin (IL-) 12 and type 1 
IFNs (IFN-α and IFN-β). These cytokines are released by macrophages and DCs upon 
activation by intracellular pathogens (Farrar, Asnagli et al. 2002). IL-12 induces the 
production of IFN-γ by these same cells, which then acts in an autocrine manner to 
generate a positive feedback loop, producing additional IL-12 (Lafaille 1998; Murphy, 
Ouyang et al. 2000). IFN-γ attachment to naïve Th cells leads to the Janus kinase (JAK) 1- 
and 2-mediated activation of the transcription factor signal transducer and activator of 
transcription (STAT) 1, which then induces the expression of T-bet. T-bet is a member of 
the TATAAAbox family of transcription factors. The production of T-bet initiates the 
remodeling of the IFN-γ gene locus, the production of IFN-γ, the expression of the IL-12 
receptor and the stabilization of its own expression through the autocrine activity of IFN-γ  
(Mullen, High et al. 2001). IFN-γ secreted by Th1 cells, stimulates surrounding naïve Th 
4
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cells to begin polarization into Th1 cells, in a self-renewing paracrine loop (Kidd 2003) 
(Fig. I.3). 
Th2 cell polarization 
Th2 cells secrete IL-4, -5, -10 and -13, which up-regulate Ab production and target 
parasitic organisms (Lafaille 1998; Kidd 2003; Wang, Kusam et al. 2006). IL-4 induces the 
production of STAT6 in naïve T cells, which in turn activates the expression of the zinc 
finger transcription factor GATA-3 (Kaplan, Schindler et al. 1996; Ouyang, Ranganath et 
al. 1998). GATA-3 and T-bet are mutually antagonistic. When IFN-γ, IL-12 and T-bet 
levels are high, GATA-3 production is inhibited, and when IL-4 and GATA-3 levels 
increase, T-bet expression is repressed (Mullen, High et al. 2001; Afkarian, Sedy et al. 
2002). Both IL-4 and TCR signaling are required to up-regulate GATA-3 transcription, 
which can induce epigenetic remodeling of the Th2 cytokine cluster of genes (Zheng and 
Flavell 1997). Once GATA-3 production reaches a certain threshold, its own gene 
expression is auto-activated, hence stabilizing the Th2 phenotype through an intrinsic 
positive feedback loop (Farrar, Asnagli et al. 2002). As Th2 cells mature, they produce 
increasing levels of IL-4, which generates a paracrine loop inducing neighboring naïve Th 
cells to develop into Th2 cells (Kidd 2003) (Fig. I.3). 
 
            Th1         Th2 
 
 
Fig. I.3: T cell polarizing factors. Cytokines bind to their receptors on Th0 cells and activate JAK-STAT 
pathways. Different combinations of JAK and STAT molecules are generated in response to different 
cytokines and induce different signaling cascades, which drive the development of the specific T cell 
phenotype. IFN-γ and interleukin IL-12 induce JAK1/2 and STAT1/3/4 to stimulate T-bet and further IFN-γ 
production, resulting in a Th1 response (left panel), whereas IL-4 triggers JAK1/3 and STAT6 to activate 
GATA-3 and a Th2 response (right panel) (adapted from Kaiko et al. 2007). 
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Th17 cell polarization 
Th17 cells secrete IL-17, IL-17F, IL-6, IL-22 and TNF-α and represent a subset of CD4+ 
effector T cells that is both distinct from and antagonized by cells of the Th1 and Th2 
lineages (Kryczek, Wei et al. 2007). Studies by Ivanov et al. demonstrated that both in 
vitro differentiation of Th17 cells and in vivo Th17-mediated inflammation are dependent 
on the transcription factor retinoic acid receptor-related orphan receptor γ-t (RORγt) 
(Ivanov, McKenzie et al. 2006). The generation of Th17 cells is inhibited by IL-4 and IFN-
γ potentially via downregulation of the IL-23 receptor (Harrington, Hatton et al. 2005; 
Park, Li et al. 2005). Th17 cells are induced by a combination of the polarizing cytokine 
IL-6 and the regulatory cytokine TGF-β (Fig. I.4). A combination of these cytokines in 
vitro induces the predominant generation of Th17 cells from naïve T cells with minimal 
numbers of regulatory T cells (Tregs). Tregs are essential for maintaining peripheral 
tolerance, preventing autoimmune diseases and limiting chronic inflammatory diseases by 
producing inhibitory cytokines such as IL-10 and TGF-β (Bettelli, Carrier et al. 2006; 
Mangan, Harrington et al. 2006; Veldhoen, Hocking et al. 2006). As TGF-β is involved in 
the development of both Tregs and Th17 cells, which may occur through the inhibition of 
IL-4- and IFN-γ-dependent pathways, it appears that IL-6, a known inhibitor of Treg 
development, plays an integral role in switching between these inflammatory and 
suppressive cell types. IL-6 acts on naïve T cells to induce the downstream expression of 
IL-21, which initiates an autocrine loop that results in self-induced expression. TGF-β then 
acts in synergy with IL-21 to induce the expression of RORγt via a STAT3-dependent 
mechanism (Korn, Bettelli et al. 2007; Zhou, Ivanov et al. 2007). The action of RORγt 
induces transcription of the genes encoding IL-17 and IL-17F (Ivanov, McKenzie et al. 
2006; Nishihara, Ogura et al. 2007; Yang, Panopoulos et al. 2007). 
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Fig. I.4: The development and function of Th17 cells. IL-6 acts to induce IL-21 secretion from T cells, 
which then acts in concert with TGF-β to induce the development of Th17 cells from naïve T cells. Th17 
cells are activated by binding of IL-23 to the IL-23 receptor (IL-23R), which is up-regulated by TGF-β and 
IL-21 stimulation. TGF-β and IL-21 activate STAT3, which induces the transcription factor RORγτ, 
responsible for Th17 differentiation (adapted from Kaiko et al. 2007). 
 
I.3 Chemokines 
Chemokines are a superfamily of small (8-10 kDa) chemotactic cytokines that function in 
leukocyte trafficking and activation by stimulating the directional migration of leukocytes 
(Reape and Groot 1999). About 40 different chemokines have been identified so far, which 
interact with about 17 different chemokine receptors expressed on different subsets of 
leukocytes. Chemokines can be classified in four subgroups according to the position of 
the N-terminal cysteines. The majority of the chemokines belong to the CC group, where 
the cysteines are adjacent to each other, followed by CXC chemokines with the first 
cysteines separated by a single amino acid residue. Fractalkine is the only member of the 
CX3C group, where the N-terminal cysteines are separated by three amino acids. 
Chemokines belonging to the C group possess only two of the four cysteines present in 
other chemokines (Moser and Willimann 2004; Weber, Schober et al. 2004). The 
chemokines involved in atherosclerosis are listed in Table I.1. 
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Chemokine Receptor Localization Target cell 
CC Chemokine   
CCL1 (I-309) CCR8 EC MM 
CCL2 (MCP-1) CCR2  MM, SMC, EC MM, TC, EC 
CCL3 (MIP-1α)  CCR1/5 TC MM, TC 
CCL4 (MIP-1β)  CCR5 TC MM, TC, SMC 
CCL5 (RANTES)  CCR1/3/5 TC MM, TC, DC 
CCL11 (Eotaxin)  CCR3 SMC B, DC 
CCL13 (MCP-4) CCR2/3 MM, EC MM, TC 
CCL17 (TARC)  CCR4/8 MM, DC TC, DC 
CCL18 (PARC)  unknown MM, DC TC 
CCL19 (ELC)  CCR7 MM, DC TC 
CCL22 (MDC) CCR7 MM, DC TC 
CXC Chemokine 
 
 
CXCL1 (GRO/KC)  CXCR1/2 MM MM, EC, SMC 
CXCL8 (IL-8)  CXCR1/2 MM MM, EC, SMC  
CXCL9 (Mig)  CXCR3 MM, EC, SMC TC 
CXCL10 (IP10)  CXCR3 ?? ?? 
CXCL11 (I-TAC)  CXCR3 MM, EC MM, TC, SMC 
CXCL12 (SDF-1α) CXCR4 MM, SMC TC, VP 
CXCL16 (SR-PSOX) CXCR6 MM, DC, SMC TC, NK 
CX3C Chemokine   
CX3CL1 (Fractalkine)  CX3CR1 SMC MM, TC 
Table I.1: Chemokines in atherosclerosis. Cells affected by chemokines involved in atherosclerosis are 
monocytes/macrophages (MM), T cells (TC), smooth muscle cells (SMC), dendritic cells (DC), endothelial 
cells (EC) and vascular progenitors (VP) (adapted from Weber et al., 2004). 
 
Chemokines evoke their biological functions by interacting with specific chemokine 
receptors expressed on leukocytes, which are named according to their ligands (CC, CXC, 
CX3C), plus R for receptor (Table I.1). These receptors are seven transmembrane-spanning 
receptors that signal through coupled heterotrimeric G proteins. Chemokine receptor 
binding induces a signal transduction cascade that leads to activation of protein kinases and 
an increase in intracellular Ca2+ (Horuk 2001). 
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Recruitment of mononuclear cells to a site of inflammation is controlled by 
chemokines and their receptors (Charo and Taubman 2004) (Charo and Ransohoff 2006). 
Chemokines bind to extracellular proteins like glycosaminoglycans (GAGs) on the cell 
surface of endothelial cells thereby generating a solid phase chemokine gradient 
(Middleton, Patterson et al. 2002). Triggering of chemokine receptors on leukocytes 
activates leukocyte integrins such as the β2 integrin lymphocyte function-associated 
antigen-1 (LFA-1) and very late antigen-4 (VLA-4), which mediate the arrest of rolling 
leukocytes on the arterial wall and their transmigration into the tissue to the site of 
inflammation (Weber, Draude et al. 1999; Ley 2003; Laudanna and Alon 2006). Each of 
the chemokines recognizes and induces the chemotaxis of a particular subset of leukocytes. 
Chemokines are not only relevant for their role in regulating leukocyte recruitment, 
but also for other activities, such as cellular activation, inflammatory mediator release, and 
promotion of T cell inflammatory responses (Gangur and Oppenheim 2000). In relation to 
DCs, chemokine receptors especially play a role in DC homing/migration into peripheral 
lymphoid tissues. In this context, the chemokine receptor CCR7 is best studied (Lieberam 
and Forster 1999; Randolph, Ochando et al. 2008). Upon stimulation by Ags, activated 
DCs acquire a migratory phenotype associated with the upregulation of CCR7 and express 
receptors linked with DC maturation, including CD40, CD80, CD86, and MHC class II 
(Sanchez-Sanchez, Riol-Blanco et al. 2006). In addition, it was observed that CCL19 
stimulation of CCR7 on DCs induces the formation of dendritic protrusions (Yanagawa 
and Onoe 2002), which have been implicated in DC function and motility. 
 
I.3.1 The DC-derived chemokine Ccl17 (thymus-and activation-
regulated chemokine, TARC) 
In 1996, CCL17 was identified as a CC chemokine constitutively expressed in the thymus 
and highly selective for T cells (Imai, Yoshida et al. 1996). Further studies showed that it 
exerts its biological effects via CC chemokine receptor 4 (CCR4) (Imai, Baba et al. 1997) 
and 8 (CCR8) (Bernardini, Hedrick et al. 1998). Furthermore, CCL17 is expressed by 
thymic DCs, LN DC and CD11c+ cells in the lung in mice (Lieberam and Forster 1999). 
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One of the main functions of DCs, besides of sampling the environment for Ags and 
migrating to peripheral lymphoid organs, is to attract T lymphocytes to the sites of Ag 
exposure. This attraction is mediated by the release of several different constitutive and 
inducible chemokines. DC-derived CC chemokine 1 (DC-CK1) (CCL18) and EBV-ligand 
chemokine (ELC) (CCL19) attract naive T cells into the T cell zone of lymphoid tissues, 
while the inflammatory chemokines monocyte chemoattractant protein (MCP)-1 (CCL2), 
macrophage inflammatory protein (MIP)-1α (CCL3), and macrophage-derived chemokine 
(MDC) (CCL22) mainly recruit activated and memory T cells (Tmem). Also CCL17 is 
known to play a role in the recruitment and migration of different T cell subsets (Lieberam 
and Forster 1999; Ross, Ross et al. 1999; Alferink, Lieberam et al. 2003). Although 
initially identified as a chemokine associated with Th2 responses, CCL17 can attract Th2 
cells as well as Th1 cells, Tmem and CD25+ Treg cells (Imai, Baba et al. 1997; Andrew, 
Ruffing et al. 2001; Iellem, Mariani et al. 2001; Alferink, Lieberam et al. 2003). In 
addition murine CCL17 expressing DCs induce both the production of the Th1 cytokine 
IFN-γ and the Th2 cytokine IL-10 in an Ag-specific manner in T cells in vitro (Alferink, 
Lieberam et al. 2003). 
Recent reports have revealed that CCL17 and its receptor CCR4 are important in the 
pathogenesis of atopic dermatitis (AD), which is considered to be a Th2-dominant disease 
especially in the acute phase (Andrew, Chang et al. 1998; Sallusto, Lanzavecchia et al. 
1998; Imai, Nagira et al. 1999; Andrew, Ruffing et al. 2001; Luther and Cyster 2001). 
Furthermore, CCL17 plays a functional role in the pathogenesis of allergic airway 
inflammation and septic shock syndrome, for which it has been described that the two 
CCR4 ligands CCL17 and CCL22 efficiently induce the transendothelial migration of fresh 
peripheral blood T cells, giving rise to T cell lines predominantly producing Th2-type 
cytokines (Chvatchko, Hoogewerf et al. 2000; Romagnani 2002). In the case of 
atherosclerosis, CCL17 is expressed in human lesions (Greaves, Hakkinen et al. 2001). 
However, a role of CCL17+ DCs in the atherogenic immune response has not been 
addressed so far. 
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I.4 Atherosclerosis 
Atherosclerosis is the underlying cause of most cardiovascular diseases, including 
coronary artery disease (CAD), ischemic gangrene, abdominal aortic aneurysms, and many 
cases of heart failure and stroke. This group of diseases constitutes currently the main 
cause of death in the Western world (Hansson, Robertson et al. 2006). Atherosclerosis is a 
progressive disease characterized by the accumulation of lipids and fibrous elements in the 
large arteries (Libby 2002). It is initiated by the formation of “fatty streaks” beneath the 
endothelium of the artery wall, followed by the development of atherosclerotic lesions, 
which are composed of different cell types such as macrophages and smooth muscle cells 
(SMCs). As the disease progresses, these lesions develop into more complex fibrous 
plaques (atheromas) (Ross 1993). Eventually these plaques can become unstable leading to 
plaque rupture. The subsequent thrombus formation rather than luminal narrowing results 
in clinical events such as myocardial infarction and stroke (Hansson 2005). 
I.4.1 Immune mechanisms in atherosclerosis 
Until the 1970s, atherosclerosis was linked with hypercholesterolemia without further 
knowledge of the mechanisms of plaque formation. Over the past decades, it has become 
evident that the retention of low-density-lipoproteins (LDL) and their oxidated forms 
(oxLDL) in the vessel wall initiates an inflammatory response of the endothelium (Skalen, 
Gustafsson et al. 2002; Leitinger 2003). Nowadays, atherosclerosis is seen as a chronic 
inflammatory disease of the vessel wall, modulated by adaptive as well as innate immune 
responses (Hansson, Robertson et al. 2006). Besides monocytes/macrophages, also T cells 
and DCs can be detected within atherosclerotic lesions (Fig. I.5) (Jonasson, Holm et al. 
1986; Hansson, Jonasson et al. 1989; Stemme, Patarroyo et al. 1992; Weber, Zernecke et 
al. 2008) and have been implicated in the initiation and/or progression of atherosclerosis. 
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Fig. I.5: Cellular composition of atherosclerotic plaques. The atherosclerotic plaque has a core containing 
lipids and debris from dead cells. Around it, a fibrous cap containing SMCs and collagen fibres stabilizes the 
plaque. Immune cells including macrophages, T cells and mast cells populate the plaque, and are frequently 
in an activated state. They produce cytokines, proteases, prothrombotic molecules and vasoactive substances, 
all of which can affect plaque inflammation and vascular function. Until complications occur, an intact 
endothelium covers the plaque (Hansson and Libby 2006). 
 
 
T cells and atherosclerosis 
Human atherosclerotic plaques contain numerous T cells. The ratio of CD4+ to CD8+ T 
cells in advanced plaques resembles that found in peripheral blood (Jonasson, Holm et al. 
1986). Lesions of early stages of experimental atherosclerosis in mice contain oligoclonal 
expansions of CD4+ cells (Paulsson, Zhou et al. 2000), indicating activation in response to 
a limited set of local Ags. An initial round of T cell activation in response to ‘athero-Ags’ 
might occur in the regional LNs, possibly after Ag presentation by DCs trafficking from 
the plaque to the LN (Angeli, Llodra et al. 2004). After entering the blood, previously 
activated memory and/or effector T cells bind cell surface adhesion molecules that are 
expressed by endothelial cells at the plaque surface and/or in the vasa vasorum, and then 
enter the plaque. Macrophages in the plaque expressing MHC-II might then present Ag to 
these T cells, leading to further rounds of activation (Hansson and Libby 2006). Multiple 
studies in atherosclerotic mice indicated that functionally distinct Th-cell subsets have 
specialized roles in atherogenesis.  
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Th1 cells seem to promote atherosclerosis (Hansson and Libby 2006). More 
specifically, in mice, Th1 cells predominate over other Th cell subsets during early lesion 
formation (Zhou, Paulsson et al. 1998). The Th1 cell response mediated by IFN-γ probably 
maintains the adaptive immune response through the induction of MHC-II expression by 
APCs and the stimulation of SMC proliferation in vivo. Atherosclerosis-prone mice that 
are deficient in T-bet, a Th1 cell-associated transcription factor as mentioned before, show 
attenuated atherosclerosis, which further illustrates that Th1 cells promote atherogenesis 
(Buono, Binder et al. 2005). 
In contrast to early stage lesions, the Th-cell balance in mouse atherosclerotic 
plaques seems to shift from a Th1 cell type to a Th2 cell type under conditions of extreme 
and persistent hyperlipidemia (Zhou, Paulsson et al. 1998). Th2 cells produce cytokines, 
including IL-4, IL-5 and IL-10, which promote allergic responses and the production of 
Abs. Several studies suggested that IL-10, which is also generated by Treg cells, can 
suppress vascular inflammation and atherosclerosis (Mallat, Besnard et al. 1999). In 
addition, experiments in hyperlipidaemic mice indicated that the Th2 cell response inhibits 
atherogenesis (Schulte, Sukhova et al. 2008). Indeed, mice deficient in T-bet (which have a 
Th2 cell bias) show a striking increase in the production of Abs that are directed against 
oxLDL-associated Ags (Buono, Binder et al. 2005). 
Other types of T cells are also known to participate in arterial diseases. CD8+ T cells 
might contribute to the formation of aneurysms by promoting the death of SMCs. 
However, the capacity of CD8+ T cells to mediate cell death in the context of 
atherosclerosis is unknown. CD4+ Treg cells have immunomodulatory functions in 
atherosclerosis in mice (Taleb, Tedgui et al. 2008). A major effector mechanism of Treg 
cells is the production of TGF-β, which seems to be crucial for their anti-inflammatory and 
anti-atherogenic activity. Studies have shown that mice with a dominant-negative form of 
the TGF-β receptor expressed by T cells had a marked increase in the development of 
atherosclerosis. Other minor T cell subsets, such as Th17 cells, can also be detected in 
plaques and may be implicated in atherogenesis (Vanderlaan and Reardon 2005). 
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DCs and atherosclerosis 
The use of pan-DC-specific markers revealed the presence of a network of DCs in the 
arterial intima of healthy young individuals (Millonig, Niederegger et al. 2001). In 
advanced human plaques, the numbers of cDCs and their precursors were increased 
compared with early lesions and they were localized in clusters with T cells mainly in the 
exposed plaque shoulder and rupture-prone regions (Yilmaz, Lochno et al. 2004; 
Bobryshev 2005). Yilmaz et al. have found that up to 70 % of DCs in the shoulders of 
vulnerable carotid plaques express markers of DC activation such as CD83 and DC-
LAMP. In contrast, patients with acute coronary syndromes have fewer circulating 
myeloid DC precursors, possibly due to increased recruitment to plaques (Yilmaz, Weber 
et al. 2006). Although their anatomical source and precursors are unclear, DC 
accumulation in regions of disturbed flow that are prone to atherosclerosis, suggests that 
inflammation-triggered DC recruitment might induce an initial immune response. In 
bioengineered arteries, adventitial cDCs stimulate autologous CD4+ T cells to produce 
IFN-γ and to infiltrate the model arterial wall, thereby breaking T cell tolerance to self Ags 
and initiating vascular inflammation (Han, Shimada et al. 2008). Modified lipoproteins, 
such as oxLDL, that are deposited in the arterial wall may display Ags that could trigger 
such an early immune activation. In line with this notion, oxLDL upregulates the 
expression of co-stimulatory molecules by DCs and increases T cell proliferation, 
although, at high concentrations it promotes DC apoptosis (Alderman, Bunyard et al. 
2002). Notably, dyslipidemia activates DCs and can inhibit their migration into LNs, 
leading to peripheral sequestration (Angeli, Llodra et al. 2004), which implies that DCs 
may participate in the local initiation of vascular inflammation. However, no depletion or 
even subset-specific depletion studies are available to support the importance of DC in 
atherosclerosis (Soehnlein and Weber 2009). The precise function of these cells therefore 
requires further elucidation. 
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I.5 Aim of this study 
It has been shown that DCs form a network within the aterial wall and increase in numbers 
in advanced human plaques. In addition, there are findings showing the upregulation of 
CCL17 transcripts in human carotid endartherectomy specimens as compared to 
macroscopically healthy carotid arteries. As the influence of CCL17 has not been further 
addressed, we aimed to clarify in this study the role of CCL17-expressing DCs in the 
inflammatory process of atherosclerosis. Knock-in mice expressing a targeted replacement 
of the Ccl17 gene by enhanced green fluorescent protein (EGFP, Ccl17E/E) were crossed 
with Apoe-/- mice and used in different atherosclerosis mouse models. As such, the extent 
of atherosclerosis progression was compared in Ccl17E/E Apoe-/- and Apoe-/- mice fed either 
a normal chow over 6 months or a high fat diet over 12 weeks. To further identify a 
contribution of CCL17 to lesion progression, Apoe-/- mice bearing established 
atherosclerotic lesions after 12 weeks of high-fat diet were lethally irradiated and 
reconstituted with Ccl17+/+Apoe-/- or Ccl17E/EApoe-/- bone marrow. Finally, a role of 
CCL17+ DCs in priming T cells in either a Th1, Th2 or Th17 dependent manner was 
investigated, using proliferation assays in vitro and in vivo, with further analysis of the 
cytokine profile (Fig. I.6). 
 
In summary, the following questions were addressed in the present study: 
- to which DC subsets belong CCL17+ DCs ? 
- do CCL17+ DCs compared with CCL17 knock-out DCs differ in typical DC functions in 
vitro and in vivo? 
- are CCL17+ DCs localized in the arterial wall? 
- do CCL17+ DCs participate in atherogenesis? 
- do CCL17+ DCs influence the polarization of Th0 cells into either Th1, Th2 or Th17 cells 
in vitro and in vivo? 
- does this T cell polarization have an impact in vivo with regards to atherosclerosis? 
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Fig. I.5: Flow chart. Brief summary of experimental procedures used in this study. 
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II Materials and Methods 
Protocols were adapted from standard protocols (Sambrook and Russell, 2001) if not stated 
otherwise. All solutions were prepared with double distilled water (Heraeus Destamat, 
Heraeus, Germany) or Millipore water (Milli-Q Plus ultrapure purification, Millipore, 
MA). Reagents were from Fluka (Buchs, Switzerland), Sigma-Aldrich (Deisenhofen, 
Germany), or Roth (Karlsruhe, Germany), if not stated otherwise. 
II.1 General equipment 
autoclave Systec 2540EL (Systec, Wettenberg, Germany) 
balance Analytical Plus (Ohaus, Pine Brook, NJ, USA) 
centrifuges Eppendorf 5417C (Eppendorf, Hamburg, Germany), Heraeus 
Labofuge 400 and Heraeus Multifuge 3 S-R (Heraeus, Osterode, 
Germany) 
flow cytometers FACSCantoII, FACSAria (BD Biosciences, San Jose, CA, USA) 
fluorescence plate reader SpectraFluor Plus (Tecan, Crailsheim, Germany) 
gel electrophoresis Mini-sub cell GT (Bio-Rad, Hercules, CA, USA) 
laminar flow hood Herasafe (Heraeus, Osterode, Germany) 
microscopes Olympus IX71 and BX51 (Olympus Optical, 
Hamburg,Germany), Leica DMLB (Leica, Wetzlar, Germany) 
PCR thermocyclers MyCycler (Bio-Rad, Hercules, CA), DNA Engine Opticon (MJ 
Research, Hercules, CA, USA) 
pH-meter InoLab level 1 (WTW, Weilheim, Germany) 
spectrometer NanoDrop (Peqlab, Erlangen, Germany) 
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II.2 Mice 
Ccl17E/+ and Ccl17E/E mice were kindly provided by Irmgard Förster (Institute for 
molecular Immunology, Düsseldorf). These mice are ‘knock-in’ mice expressing a targeted 
replacement of the Ccl17 gene by enhanced green fluorescent protein (EGFP, Ccl17E/E) 
(Fig.II.1). The chemokine CCL17 is almost exclusively expressed by a subset of DCs. 
Therefore, Ccl17E/+ reporter mice were used to visualize these cells in atherosclerosis, 
while Ccl17E/E mice were used to study the pathogenic role of CCL17-expressing DCs and 
their effector function in atherosclerosis. Ccl17E/+ and Ccl17E/E mice were crossed with 
Apolipoprotein E deficient (Apoe-/-) mice to establish Ccl17E/+ Apoe-/- and Ccl17E/E Apoe-/- 
mice in the local animal facilities. Ccl17E/- Apoe-/- and Ccl17E/E Apoe-/- mice and respective 
Apoe-/- littermates were in a C57BL/6J background.  
 
 
 
 
Fig. II.1: Generation of CCL17 reporter and CCL17-deficient mice. Targeting strategy for insertion of 
the EGFP cDNA into the murine Ccl17 locus. The murine genomic Ccl17 locus with partial restriction map 
(top), the targeting construct (middle), and the targeted allele before and after neomycin deletion (bottom) are 
shown. The 3 exons of the Ccl17 gene are indicated as gray boxes and the hybridization probe used for 
Southern blot analysis as a black bar. The EGFP reporter gene and the neomycin resistance cassette are 
indicated as open boxes, FRT-sites as black lines. Restriction sites: B, BamHI; Xa, XbaI; Xo, XhoI. 
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OT-II transgenic mice were obtained from the local animal breeding facility 
(University Hospital, Aachen). These mice express a mouse α-chain and β-chain TCR that 
pairs with the CD4 coreceptor and is specific for chicken ovalbumin 323-339 (OVA-2) 
presented by MHC class II molecules. CD4+ T cells isolated from these mice demonstrate 
a dose-dependent proliferative response to OVA-2 peptide. 
CD11c-EYFP mice were kindly provided by Michel C. Nussenzweig (Laboratory of 
Molecular Immunology, Rockefeller University, New York). Wild-type C57BL/6 and 
Apoe-/- mice were obtained from the local animal breeding facility.  
Transgenic mice were fertile and showed no phenotypical abnormalities. All studies 
with mice were approved by local authorities and complied with the German animal 
protection law. 
 
 
II.3 Chemokines and recombinant proteins 
The chemokine CCL17 was purchased from R&D Systems (Minneapolis, MN, USA) and 
ELC was from PeproTech (Rochy Hill, NJ, USA). The different growth-factors for DC 
culture (II.5.1) were either purchased from PeproTech (GM-CSF and FLT3-ligand) or 
from Sigma-Aldrich (long-range IGF-1 and Dexamethasone). Recombinant hyperIL-6 was 
kindly provided by Dr. S. Rose-John (Kiel, Germany) and recombinant SCF by Prof. Dr. 
M. Zenke (Aachen, Germany). 1,1`-dioctadecyl-3,3,3`,3`-tetramethylindocarbo-cyanine 
perchlorate (Di)-oxidized LDL was purchased from Intracel (Frederick, MD, USA). OVA-
2 (323-339) peptide was from AnaSpec (San Jose, CA, USA). 
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II.4 Antibodies 
II.4.1 Primary Antibodies 
anti-SMA mouse anti-human anti-actin mAb (clone 1A4, Dako, Glostrup, Denmark) 
MOMA-2 rat anti-mouse mAb, macrophage marker (clone MCA519, AbD Serotec, 
Düsseldorf, Germany) 
CD3 mouse anti-human mAb, T cell marker (clone PC3/188A, Santa-Cruz 
Biotechnology) 
pSTAT1 rabbit anti-mouse pAb, signal transducer and activator of transcription 
(Cell Signaling Technology, Danvers, MA, USA)  
pSTAT3 rabbit anti-mouse pAb, signal transducer and activator of transcription 
(Cell Signaling Technology) 
pSTAT6 rabbit anti-mouse pAb, signal transducer and activator of transcription 
(Cell Signaling Technology) 
  
II.4.2 Directly conjugated antibodies 
MHC-II-PE rat anti-mouse mAb, PE-conjugated, APC marker (clone 2G9, 
BD Pharmingen) 
MHC-II-APC rat anti-mouse mAb, APC-conjugated, APC marker (clone 
M5/114.15.2, BioLegend, San Diego, CA, USA) 
CD11c-PE-Cy7 rat anti-mouse mAb, PE-Cy7-conjugated, DC marker (clone 
N418, eBiosciences, San Diego, CA, USA) 
CD11b-PerCP rat anti-mouse mAb, PerCP-conjugated, DC and monocyte 
marker (clone M1/70, BD Pharmingen) 
CD8a-PE or PE-Cy7 rat anti-mouse mAb, PE or PE-Cy7-conjugated, DC and T 
cell marker (clone 53-6.7, eBioscience) 
PDCA-1-PE rat anti-mouse mAb, PE-conjugated, pDC marker (clone 
JF05-1C2.4.1, Miltenyi Biotec) 
440c-APC rat anti-mouse mAb, APC-conjugated, pDC marker (clone 
eBio440c, eBioscience) 
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CD115-PE rat anti-mouse mAb, PE conjugated, monocyte marker (clone 
AFS98, eBiosciences) 
Gr-1-PerCP rat anti-mouse mAb, PerCP-conjugated, mature granulocyte 
marker (clone RB6-8C5, BD Pharmingen)  
CD4-PE or APC  rat anti-mouse mAb, PE or APC-conjugated, DC and T cell 
marker (clone RM4-5, eBioscience) 
CD3-PerCP or APC rat anti-mouse mAb, PerCP or APC-conjugated, T cell 
marker (clone 145-2C11, eBioscience) 
CD25-APC rat anti-mouse mAb, APC-conjugated, Treg marker (clone 
PC61.5, eBioscience) 
CCR4-APC rat anti-mouse mAb, APC-conjugated, T cell marker (clone 
2G12, BioLegend) 
CD19-PerCP rat anti-mouse mAb, PerCP-conjugated, B cell marker (clone 
1D3, BD Pharmingen) 
B220-PE-Cy7 rat anti-mouse mAb, PE-Cy7-conjugated, B cell and DC 
marker (clone RA3-6B2, eBioscience) 
F4/80-Biot rat anti-mouse mAb, biotinylated, mature macrophage marker 
(clone A3-1, Serotec) 
CD45-APC-Cy7 rat anti-mouse mAb, APC-Cy7-conjugated, leukocyte marker 
(clone 30-F11, BD Pharmingen) 
CD80-APC rat anti-mouse mAb, APC-conjugated, costimulatory 
molecule marker (clone 16-10A1, eBioscience) 
CD86-PE rat anti-mouse mAb, PE-conjugated, costimulatory molecule 
marker (clone GL1, eBioscience) 
CD40-APC rat anti-mouse mAb, APC-conjugated, costimulatory 
molecule marker (clone 1C10, eBioscience) 
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II.4.3 Secondary antibodies 
donkey-anti-rat-IgG cyanine 3 (Cy3)-conjugated (Jackson ImmunoResearch, 
West Grove, PA) 
donkey-anti-mouse-IgG Cy3-conjugated (Santa-Cruz Biotechnology) 
  
II.4.4 Blocking antibodies 
CCL17  rat anti-mouse mAb, clone 110904 (R&D Systems) 
  
II.4.5 Depletion antibodies 
CD4  rat anti-mouse mAb, clone GK1.5 (BioLegend) 
  
II.5 Cell culture 
Cell culture was performed under sterile conditions in a laminar flowhood. Cells were 
maintained in a CO2-incubator at 37°C and a humidified 5% CO2 atmosphere. Cells were 
cultured in growth medium (RPMI 1640) supplemented with 10% (v/v) fetal calf serum 
(FCS), 2 mM L-glutamine and penicillin (100 U/mL)/streptomycin (100 µg/mL) (PAA, 
Pasching, Austria) to avoid contamination with bacteria. FCS was incubated at 56°C for 30 
min to inactivate the complement proteins and stored at -20°C until use. All media and 
solutions used for cell culture were from Gibco if not stated otherwise and purchased 
sterile or sterilized through a 0.2 µm filter. Cultured cells were regularly tested to be 
mycoplasma free by the VenorGeM Mycoplasma detection kit (Minerva Biolabs, Berlin, 
Germany). 
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II.5.1 Culturing of bone marrow-derived myeloid DCs (BMDCs) 
For generation of myeloid DCs, bone marrow suspensions were prepared from Ccl17E/+ 
and Ccl17E/E mice. Bone marrow cells were obtained by flushing the femur and tibia with 
growth medium (II.5). Cells were seeded at 2 x 106 cells/ml in growth medium containing 
recombinant murine SCF (100 ng/ml), FLT3-L (25 ng/ml), recombinant long-range IGF-1 
(40 ng/ml), rIL-6/soluble IL-6R fusion protein (5 ng/ml), murine GM-CSF (25 U/ml), and 
dexamethasone (10-6M). After three days in culture, cells were subjected to Ficoll-
Hypaque density gradient centrifugation (density, 1.077 g/ml; Eurobio, Paris, France). 
Medium with growth factors was replenished every two days, and cells were maintained at 
2 x 106 cells/ml cell density. After seven days, differentiation into DCs was induced in 
culture medium supplemented with murine GM-CSF (250 U/ml) alone. Every two days, 
medium was replenished, and cells were maintained at 2 x 106 cells/ml cell density. After 
ten days of differentiation reasonable numbers of mature potent myeloid DCs were 
generated. Cells were then used for further analysis. 
II.5.2 Cell isolation after tissue digestion 
For flow cytometric analysis of tissues, LNs (brachial, axillary, cervical, popliteal, and 
inguinal) or spleen were digested with collagenase D free of tryptic activity (Sigma-
Aldrich) for 30 min at 37°C. Cells isolated from spleen were lysed with red blood cell lysis 
buffer for 5 min. Single cell suspensions were generated by pressing LN or spleen cells 
through a 70-µM cell strainer. Aorta was excised and digested with 1.8 mg/ml of LPS-free 
Blendzyme Liberase III (Roche, Mannheim, Germany) diluted 1:20 in RPMI 1640 for 30 
min at 37°C. Hanks`complete solution was added, and cells were passed through a 70-µm 
strainer. Cells were then used for further analysis. 
Red blood cell lysis buffer: 
0.8% ammonium chloride, 10 mM potassium hydrogen carbonate (KHCO3), 0.1 mM 
EDTA, pH 8.0 
Hanks´complete solution: 
1 x HBSS, 0.1% BSA and 5 mM EDTA 
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II.5.3 Isolation of CD4+ T cells 
CD4+ T cells were isolated from secondary lymphoid organs of wild-type (wt) mice via 
depletion of non-CD4+ T cells. For this purpose, the CD4+ T cell Isolation Kit (containing 
a cocktail of biotin-conjugated antibodies against CD8a, CD45R, CD11b, CD49b and Ter-
119, as well as magnetic anti-biotin MicroBeads) and a separation column (Miltenyi 
Biotec, Bergisch-Gladbach, Germany) were used according to the recommended protocol, 
allowing a negative selection of CD4+ T cells. 
Briefly, the freshly isolated LN and spleen cells were mixed with the cocktail of 
biotin-conjugated antibodies and incubated for 10 min at 4°C. After washing with MACS 
buffer, the cells were mixed with magnetic anti-biotin microbeads, incubated for 15 min at 
4°C and washed. The magnetically labeled cells were retained in a separation column 
placed in a magnetic field, whereas unlabeled CD4+ T cells were recovered in the eluate. 
MACS buffer: 
PBS, 0.5% BSA, 2 mM EDTA 
II.5.4 Cell sorting 
CCL17+ DCs were isolated by sorting for EGFP expression. For the separation of OT-II T 
cells from DCs after coculture (II.8.4), cells were stained for CD4 with a mAb (II.4.2). 
Cells were sorted with a BD FACSAria (BD Bioscience), and used in RT-PCR, oligo 
microarray, phagocytosis, migration, chemotaxis and proliferation assays. 
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II.6 Biomolecular methods 
II.6.1 Quantification of RNA 
RNA concentration was determined by measuring the absorbance at 260 nm (A260) in a 
spectrophotometer. The absorbance at 280 nm was also measured to estimate DNA and 
RNA purity. Pure DNA or RNA has an A260/A280 ratio of 1.8-2.0 at pH 7.0. 
II.6.2 Quantitative real-time polymerase chain reaction (PCR) 
To determine cytokine (Il-2, Ifn-γ, Il-4, Il-10, Il-17a or Foxp3) and chemokine receptor 
(Ccr7, Cxcr4, Cxcr6, Cxcr2 or Ccr2) gene expression, a real-time PCR was performed 
using the SYBR Advantage qPCR Kit (Clontech, Saint-Germain-en-Laye, France) and 
specific primers according to manufacturer’s protocol. The real-time PCR technique is 
based on the specific fluorescence properties of SYBRGreen when bound to double-
stranded DNA, i.e. the increase in double-stranded DNA can be directly detected. Thus, the 
increase of fluorescence over the reaction time can be associated with the initial mRNA 
concentration. 
RNA from DCs, OT-II T cells or LNs was isolated using the RNeasy Mini Kit 
(Qiagen, Hilden, Germany) following digestion of genomic DNA using the RNase-free 
DNase set (Qiagen) according to the manufacturer’s protocol. After determination of the 
RNA amount (II.6.1), up to 1 µg total RNA was reverse-transcribed into cDNA with the 
M-MLV RT Kit (Promega, Madison, WI, USA) using oligo-dT primers (Sigma-Aldrich) at 
37°C for 1 h. 20 ng cDNA were assessed in the real-time PCR reaction. The housekeeping 
gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a reference gene. 
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Reverse transcription: 5 µl 5x reverse transcription buffer 
 0.5 µl dNTP mix (20 mM each) 
 1.1 µl 10 µM oligo-dT primer 
 1 µl reverse transcriptase enzyme 
 1 µg template RNA 
 H2O to a final volume of 100 µl 
 
Real time-PCR 2 µl cDNA or H2O 
 13 µl 2x QuantiTect SYBR Green PCR Master Mix 
 forward primer to a final concentration of 0.5 µM 
 reverse primer to a final concentration of 0.5 µM 
 RNase free water to final volume of 25 µl 
Real time-PCR Program:  
1. Initial activation 95°C, 15 min 
2. Denaturation  94°C, 15 sec 
3. Annealing  58°C, 30 sec  
4. Extension  72°C, 30 sec 
5. Plate read  
 
The relative mRNA expression is calculated as follows: 
∆Ct  = Ct(target gene) - Ct(reference gene) 
∆∆Ct  = ∆Ct(sample) - ∆Ct(control sample) 
relative mRNA expression:   Ct)(2 ∆∆−  
Ct: Cycle number at which the fluorescence intensity exceeds a determined threshold 
 
 
× 45 
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Primers for real-time PCR: 
mouse Il-2: 5'-CCTGAGCAGGATGGAGAATT-3', 
 5'-TCCAGAACATGCCGCAGAG-3' 
mouse Ifn-γ:  5'-TGGCTCTGCAGGATTTTCAT-3',  
 5'-TCAAGTGGCATAGATGTGGA-3' 
mouse Il-4:  5'-CAACGAAGAACACCACAGAGAG-
 ATGAATCCAGGCATCGAAAAGC-3' 
mouse Il-10:  5'-TGCACTACCAAAGCCACAAGG-3',  
 5'-TGGGAAGTGGGTGCAGTTATTG-3'  
mouse Il-17a:  5'-CCTAAGAAACCCCCACGTTT-3',  
 5'-CAGTTTGGGACCCCTTTACA-3' 
mouse Foxp3 5'-TTGGTTTACTCGCATGTTCG-3', 
 5'-AGGGATTGGAGCAGCACTTGTTG-
mouse Ccr7 5'-GATTTCTACAGCCCCCAGAG-3', 
 5'- GAAGCACACCGACTCGTAC -3' 
mouse Cxcr4 5'-TCTGTGACCGCCTTTACCC-3', 
 5'-GTAACAGGAGAGGATGACGATG-3' 
mouse Cxcr6 5'-TGGGTCTTTGGCACAGTCATG-3', 
 5'-CCCAAATGAGCAAGCAAATGAC-3' 
mouse Cxcr2 5'-GTCCCATGCCACTCAGAGAA-3', 
 5'-CAGGGCAAAGAACAGGTCAG-3' 
mouse Ccr2 5'-GACAAGAAACTAGCAGCCCATA-3', 
 5'-GTTGCTGTGAGGTCCATCTGA-3' 
mouse Ccl17 5'-GCTGCCTGGATTACTTCAAAG-3' 
 5'-GGACAGTCAGAAACACGATGG-3' 
mouse Gapdh 5'-CCATCACCATCTTCCAGGAG-3', 
 5'-GTGGTTCACACCCATCACAA-3' 
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human CCL17 5'-GCTCGAGGGACCAATGTG-3' 
 5'-GACCTCTCAAGGCTTTGCA-3' 
human GAPDH 5'-GCCTCAAGATCATCAGC-3', 
 5'-ACCACTGACACGTTGGC-3' 
 
 
II.6.3 Oligo microarray 
To determine differences in gene regulation in BMDCs of Ccl17E/+ and Ccl17E/E mice or 
OT-II T cells three days after coculture with OVA-2 pulsed DCs, oligo microarray analysis 
were performed. 
DCs and OT-II T cells were sorted with the FACSAria (BD Bioscience) (II.5.4) and 
total RNA was isolated using the RNeasy Mini Kit (Qiagen) following the manufacturer’s 
instructions. Biotin-labeled cRNAs, known as labeled cRNA targets, were generated using 
TrueLabeling-AMP Linear RNA Amplification Kit following manufacturer’s protocol 
(Sabiosciences, Frederick, MD, USA). Briefly, total RNA (5 µg/array) was first converted 
to cDNA at 42°C for 50 min. These cDNAs were then in vitro transcribed to cRNAs in the 
presence of biotin-16-UTP (Roche). Biotin-labeled cRNAs were purified using the RNeasy 
Mini Kit (Qiagen). The concentration of cRNAs was measured with a NanoDrop 
spectrophotometer (II.6.1). The array membranes were hybridized with these biotin-labeled 
targets (5 µg/array) at 60°C for 17 hours, after which each membrane was first washed 
with wash solution I and then with wash solution II at 60°C for 15 min. Chemiluminescent 
detection steps were performed by subsequent incubation of the membranes with alkaline 
phosphatase–conjugated streptavidin and CDP-Star substrate. The images were captured 
using LAS 3000 (Fuji, Düsseldorf, Germany). One picture per 5 min was taken over a 
period of 60 min. After conversion to JPG with multi gauge 3.0, the pictures of the scanned 
array membranes were evaluated with GEArray Expression Analysis Suite 2.0 
(Sabiosciences). For quantification, the signal intensity was first measured with a local 
background subtraction method. These subtracted intensities were then normalized via 
house-keeping genes and negative controls (e.g. blanks) to obtain a relative intensity for 
each spot. These relative intensities were used to compare samples. 
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Wash solution I: 
2 x SSC, 1% SDS 
Wash solution II: 
0.1 x SSC, 0.5% SDS 
 
II.7 Protein assays 
II.7.1 Flow cytometry 
Flow cytometry can be used to analyze cells by their size, granularity and protein 
expression (by e.g. fluorescence-conjugated detection Abs) or to sort cell populations 
(FACS = Fluorescent activated cell sorting). In a buffer stream, one cell at a time passes by 
an argon laser, which excites fluorescently labeled cells. Measurements of the size 
(forward scatter) and granularity (sideward scatter) are independent from the fluorescence 
signal. 
Measurement of fluorescence intensity using fluorescence-labeled Abs was 
performed to examine and distinguish different cell populations in LNs and spleen by the 
expression of different markers on the cell surface. In addition, the maturation status of 
DCs was examined using Abs against costimulatory molecules, e.g. CD40. To determine 
the polarization of CD4+ T cells into different Th subsets, intracellular cytokine staining 
was performed. The results were displayed as dot plots showing the logarithmic 
distribution of the fluorescence intensity or as diagrams demonstrating the change in mean 
fluorescence intensity (MFI) or percentage (%). 
For receptor expression determination, up to 1 × 106 cells were resuspended in FACS 
staining buffer with specific fluorescence-conjugated Abs (1:100) and incubated for 20 
min on ice. The cells were washed with Hanks` complete and analyzed immediately by 
flow cytometry in a FACSCantoII (BD Biosciences). For intracellular staining, all steps 
were performed at RT. Cells were fixed in 2% paraformaldehyde (PFA) for 20 min and 
permeabilized by using 0.5% saponin for 10 min. Then, cells were stained with specific 
Abs in FACS staining buffer for 20 min. The cells were washed with Hanks` complete and 
analyzed by flow cytometry in a FACSCantoII (BD Bioscience) and evaluated with 
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FlowJo Software (Tree star, Inc, Ashland, OR, USA), if not stated otherwise. As control, 
the fluorescence minus one (FMO) method was used. 
FACS staining buffer: 
PBS, 2% BSA, 2% mouse serum, 2% rabbit serum, 2% human serum 
II.7.2 Bead array 
Supernatants obtained from proliferation assays in vitro using cocultures of OT-II cells and 
DCs (II.8.4) were analyzed for T helper cytokines using flow cytomix Th1/Th2 10 plex 
assay (BenderMedSystems, Wien, Austria). This kit allows the simultaneous detection and 
quantification of soluble murine GM-CSF, IFN-γ, IL-1α, IL-2, IL-4, IL-5, IL-6, IL-10, IL-
17 and TNF-α in a single sample. The bead-based assay follows the same principle as a 
sandwich immunoassay. Fluorescent polystyrol beads are coupled with Abs specific to the 
analytes to be detected. Beads are differentiated by their sizes and distinct spectral 
signature by flow cytometry. Two sets of beads with different sizes (4 µm and 5 µm) are 
used in this assay. Each of the two sizes consists of bead populations which are 
differentiated by varying intensities of an internally fluorescent dye. The dye emits in the 
far red (690 nm), which is detected in the FL-3/FL-4 channel. The combination of the two 
different bead sizes and different internal dye intensities makes it possible to distinguish up 
to 20 bead sets in one fluorescent channel. Streptavidin-phycoerythrin (PE), which binds to 
the biotin conjugate, emits at 578 nm and is detected in the FL-2 channel and allows the 
quantification of the analyte. 
For determination of cytokines released by OT-II T cells, a mix of coupled beads is 
incubated with the supernatants for 2 h at RT. During the incubation, analytes in the 
supernatants bind to the Abs coupled to the beads. At the same time, a biotin-conjugated 
Ab mix is added, which binds to the analytes bound to the capture Abs. Afterwards, 
streptavidin-PE is added for 1 h at RT (Fig.II.1). Sample were examined by FACSCantoII 
(BD Bioscience), the results were analyzed using the FlowCytomix Pro 2.2 analysis 
software. Standard curves based on the MFI of cytokine beads were used for quantifying 
sample cytokines concentrations. 
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Fig.II.1: Bead array. From left to right: Beads are coated with Abs specifically reacting with each of the 
analytes to be detected in the supernatants. The analyte present in the supernatant binds to each Ab linked to 
the fluorescent bead. A biotin-conjugated second Ab mixture is added, which bind to the analytes captured by 
the first Abs. Streptavidin-PE is added, binds to the biotin conjugate and emits fluorescent signals. 
 
II.7.3 Enzyme-linked immunosorbant assay (ELISA) 
The IgG concentrations against oxLDL in the sera of Apoe-/- and Ccl17E/E Apoe-/- mice 
were detected via ELISA using the mouse immunoglobulin isotyping ELISA kit (BD 
Bioscience). A 96 well polystyrene microplate was coated with oxLDL (10 µg/ml) 
overnight (o.n.). Sera were diluted 1:100 and added for 1 h, followed by several washing 
steps. Specific anti-mouse IgG-Abs, e.g. IgG1, conjugated with biotin serves as detection 
Ab. After binding of streptavidin conjugated with HRP and reaction with a substrate, a 
color change according to the protein content was measured at a wavelength of 450 nm 
with an ELISA reader and evaluated via XFluor™ Software (Tecan, Crailsheim, 
Germany). 
II.7.4 Histochemistry  
The extent of atherosclerosis was assessed in aortic roots and on thoracoabdominal aortas 
by staining for lipid depositions with oil-red-O (Sigma-Aldrich), followed by 
quantification by computerized image analysis (Diskus Software, Hilgers, Königswinter) 
and Leica Qwin Imaging software (Leica Ltd, Cambridge, UK). Oil-red-O staining was 
performed on 5-µm transversal sections through the heart and the aortic roots or on 
thoracoabdominal aorta, which was opened longitudinally. Sections or thoracoabdominal 
aortas were incubated in 0.5% oil-red-O solution for 30 min. The percentage of lipid 
deposition was calculated by dividing the stained area by the total surface. 
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II.7.5 Immunofluorescence 
To determine the relative content of macrophages, CD3+ T cells, and SMCs, 5 µm tissue 
sections of aortic roots of Apoe-/- and Ccl17E/E Apoe-/- mice were stained with mAbs for the 
specific markers (MOMA-2, CD3 and SMA) (II.4.1). For detection, Cy3-conjugated 
secondary Abs were used (II.4.3). Nuclei were counter-stained by 4',6-Diamidino-2-
phenylindol (DAPI). The relative macrophage, T cell or SMC content was determined by 
quantifying the area positive for MOMA-2, CD3 or SMA. Images were recorded with a 
Leica DMLB fluorescence microscope and charge couble device (CCD) camera. 
II.7.6 Multiphoton microscopy 
For detecting EGFP+ or EYFP+ DCs in the aterial wall or in atherosclerotic lesions, 
multiphoton microscopy was used. This technique uses pulsed long-wavelength laser light 
to excite fluorophores within the tissue being observed. The fluorophore absorbs the 
energy from two long-wavelength photons which must arrive simultaneously in order to 
excite an electron into a higher energy state, from which it can decay, emitting a 
fluorescence signal. It differs from traditional fluorescence microscopy in which the 
excitation wavelength is shorter than the emission wavelength, as the summed energies of 
two long-wavelength exciting photons will produce an emission wavelength shorter than 
the excitation wavelength. Therefore, multiphoton microscopy has the advantage to scan 
up to 300 µm deep in the tissue. 
Carotid arteries were mounted in a perfusion chamber (Fig.II.2 A) and imaged using 
a Bio-Rad 2100MP, (Biorad, Hemel Hempstead, GB) or a LaVision Trimscope 
multiphoton system (LaVision GmbH, Bielefeld, Germany) coupled to an Olympus 
BX61WI microscope (Olympus GmbH Hamburg, Germany). Aortas were opened 
longitudinally through to the aortic valve region, embedded in agarose gel (1.5% in 
HBSS). Excitation lasers (Biorad: Spectra physics Tsunami; LaVision: MaiTai HP) were 
tuned at 850 nm (to visualize EYFP and second harmonic generation of collagen) or 800 
nm (to visualize EGFP and fluorescent probes), and a Nikon 60X (NA 1.0) or an Olympus 
20X (NA 0.95; water dipping) objective were used. An increase in magnification was 
achieved by internal optical zoom (Biorad) or by reducing the field of view while 
maintaining pixel resolution (LaVision). For detection of the emitted fluorescent signals, 
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three photo multiplier tubes (PMTs) were tuned to corresponding parts of the emission 
spectra of the fluorescent markers: second harmonic generation (SHG) 400-470 nm (PMT 
1), EGFP, 500-550 nm (PMT 2); YFP, 530-560 nm (PMT 2) and MHC-II-PE 
(eBioscience), 560-600 nm (PMT 3), propidium iodide (Molecular Probes) 560-600nm 
(PMT 3). For simultaneous imaging of a combination of fluorescent markers, each PMT 
was tuned for minimal bleed-through. From each PMT, separate images were obtained and 
combined into RGB images. Images were collected in xy directions, and series of xy 
images were obtained at successive depth positions (z-stack) for reconstruction of 3D-
images (Fig.II.2 B). Image analyses were performed using Image-Pro Plus 6.2 with 3D-
reconstructor 5.1 (Media Cybernetics, Silver Spring, USA). 
 
 
 
Fig.II.2: A Schematic representation of a vessel perfusion chamber used to mount isolated arteries. The 
distance between the two pipettes is adjustable for correction of the arterial length after dissection. Fluid 
capacity is 10 ml. Inset: mouse uterine artery mounted on two glass pipettes with sutures, length adjusted, 
and pressurized to 80 mm Hg. B 3D reconstruction (size of arterial section = 309 x 309 x 315 µm) of a 
uterine artery stained for elastin and nuclei with superimposed coordinate system and a z-stack of optical xy-
slices (Megens, Reitsma et al. 2007) 
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II.8 Functional assays 
II.8.1 Phagocytosis 
In the immune system, phagocytosis is a major mechanism used to remove pathogens and 
cell debris. To determine the ability of BMDCs (II.5.1) to take up Ags, a phagocytosis 
assay was performed. 1 x 106 cells were incubated with Di-oxLDL (10 µg/ml) for 3 h. 
Cells were washed with Hanks`complete medium and analyzed by flow cytometry. 
II.8.2 Chemotaxis 
Transmigration of BMDCs (II.5.1) toward a chemokine gradient was investigated using 
Transwell filter inserts (Costar, Cambridge, MA, USA; 3 µm pore size). 2 x 105 cells in 
migration medium were allowed to transmigrate toward ELC (50 ng/ml) in the bottom 
chamber for 90 min. Input and migrated cells were counted by flow cytometry. 
Migration medium: 
RPMI 1640, 0.5% BSA 
II.8.3 Transmigration 
In vitro transmigration assays were performed to analyze the T cell migration of CD4+ 
cells towards CCL17-producing DCs. CD4+ T cells were isolated via CD4+ T cell isolation 
kit (Miltenyi Biotec) (II.5.3) from spleen and LNs of C57BL/6 mice. Sorted Ccl17E/+ 
EGFP+ and Ccl17E/E EGFP+ DCs were added to 48-well tissue culture plates in a final 
volume of 600 µl migration medium. Transwell filter inserts (Costar; 3 µm pore size) were 
placed in each well and isolated CD4+ T cells added to the upper chambers. The cells were 
allowed to migrate into the lower chambers at 37°C for 2 h. The migrated cells in the lower 
chambers were stained with mAb for indicated surface markers and counted by flow 
cytometry.  
Migration medium: 
RPMI 1640, 0.5% BSA 
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II.8.4 Proliferation 
In vitro proliferation assays were performed to analyze the influence of CCL17-
producing DCs in terms of T cell activation. Therefore CD4+ T cells were isolated from 
spleen and LNs of OT-II mice using CD4+ T cell isolation kit (Miltenyi Biotec) (II.5.3). 
After isolation, CD4+ OT-II T cells were labeled with carboxyfluorescein succinimidyl 
ester (CFSE) (Fluka) by incubation with 5 µM CFSE in labeling medium for 10 min. 
Labeling was stopped by adding one volume of labeling medium, and cells were 
washed an additional two times. Ccl17E/+ and Ccl17E/E derived BMDCs were sorted for 
EGFP+ or EGFP- cells and pulsed with 1 µg/ml OVA-2 peptide for MHC class II-
restricted T cell stimulation. Untreated DCs were used as control.  
A total of 3 x 104 OT-II T cells were cocultured with 1 x 104 DCs in 200 µl of 
growth medium (II.5) in a 96-well flat-bottom microtiter plate for 72 h at 37°C with 
additional GM-CSF (25 U/ml). After three days, OT-II T cells were harvested and T 
cell proliferation monitored by CFSE dye dilution was analyzed by flow cytometry. The 
supernatant was kept for cytokine analysis (II.7.2). To further determine the exact 
influence of CCL17 on T cell proliferation, murine CCL17 or blocking CCL17 Ab was 
added. 
Labeling medium: 
RPMI 1640, 10% FCS 
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II.9 Animal experiments 
II.9.1 Mouse model of atherosclerotic disease 
Female Apoe-/-, Ccl17E/+ Apoe-/- and Ccl17E/E Apoe-/- mice were fed a normal chow or, at 8 
weeks of age, an atherogenic diet containing 21% fat (Atromin) for 12 weeks, after which 
they were sacrificed. Hearts were harvested by in situ perfusion fixation with 4% PFA. The 
extent of atherosclerosis was assessed in aortic roots and thoracoabdominal aortas by 
staining for lipid deposition with Oil-red-O (II.7.4). The relative content of macrophages, 
CD3+ T cells and SMCs was determined by immunofluorescence (II.7.5). Cytokine 
analysis of LN cells was performed using real-time PCR (II.6.2). 
II.9.2 Bone marrow transplantation 
To assess a contribution of CCL17 to lesion progression, Apoe-/- mice were lethally 
irradiated and reconstituted with Ccl17+/+Apoe-/-, Ccl17E/+Apoe-/- or Ccl17E/EApoe-/- bone 
marrow. For bone marrow transplantation femurs and tibias were aseptically removed from 
donor Ccl17E/E Apoe-/-, Ccl17E/+ Apoe-/- or Apoe-/- control mice. Marrow cavities were 
flushed and single cell suspensions prepared. Donor cells (3 × 106) were administered by 
tail vein injection into Apoe-/- mice bearing established atherosclerotic lesions after 12 
weeks of high-fat diet 24 h after an ablative dose of whole-body irradiation (2x6 Grays 
(Gy)). Afterwards, transplanted mice were fed again a high-fat diet over 12 weeks and 
sacrificed. Again, hearts and thoracoabdominal aortas were harvested and stained for lipid 
deposition (II.7.4). 
II.9.3 Adoptive CD4+ T cell transfer 
Female Apoe-/- mice of 9 weeks of age were treated with anti-mouse CD4 depletion 
antibody (GK1.5) (BioLegend). For in vivo treatment with GK1.5, mice were injected 
intraperitoneally with a total of 600 µg of GK1.5 antibody. This was given in two doses of 
300 µg each, respectively 7 and 4 days prior to adoptive CD4+ T cell transfer. These CD4+ 
T cells were isolated from spleen and LNs of Apoe-/-Ccl17E/E and Apoe-/- mice using the 
CD4+ T cell isolation kit (Miltenyi Biotec). 5 x 106 CD4+ T cells were injected into the tail 
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vein of the CD4+ T cell-depleted Apoe-/- mice, as described above. Apoe-/- mice without 
anti-CD4 depletion antibody treatment and T cell injection served as control. All mice 
were placed on an atherogenic diet for four weeks and sacrificed. Again, hearts and 
thoracoabdominal aortas were harvested and stained for lipid deposition (II.7.4). The 
relative content of macrophages was determined by immunofluorescence (II.7.5). Cytokine 
analysis of LN cells was performed using real-time PCR (II.6.2). 
II.9.4 Recruitment assays 
For studying the recruitment of CD4+ T cells via CCL17 in vivo, the airpouch model was 
used. Mice were subcutaneously injected in the back at days 0 and 4 with 5 ml sterile air to 
create an air pouch. At day 7, 1 ml sterile PBS containing recombinant murine CCL17 (20 
ng/ml) (R&D) was injected into the pouch. 4 h later, the pouch was lavaged with 
Hanks`complete. Injection of PBS without the recombinant protein into the air pouch 
served as control. Cell counts and viability were determined using trypan blue exclusion. 
Single cell suspensions were stained with indicated surface markers and counted by flow 
cytometry. 
The migration of CD11c+ vascular DCs, sorted from digested aortas (II.5.2) of CD11c-
EYFP mice (5x105), and of sorted EGFP+Ccl17E/+ and EGFP+Ccl17E/E DCs (5x106) was 
assessed after injection into the footpad of recipient C57Bl/6 mice. After 18 h, popliteal 
LN cells were isolated (II.5.2) and migrated DCs were analyzed via flow cytometry and 
immunofluorescence microscopy. 
For T cell homing assays, isolated and CFSE-labeled CD4+ T cells (II.8.4) (5x105) were 
injected intravenously into untreated Ccl17+/+ Apoe-/- or Ccl17E/E Apoe-/- mice. Recruitment 
to peripheral and para-aortic LNs was assessed after four days by flow cytometry. 
II.9.5 Proliferation in vivo 
CD4+ T cells were isolated from spleen and LNs of OT-II mice using the CD4+ T cell 
isolation kit (Miltenyi Biotec) (II.5.3). CD4+ OT-II cells were labeled with CFSE (Fluka) 
by incubation with 5 µM CFSE in labeling medium for 10 min. Labeling was stopped by 
adding one volume of cell groth medium (II.5), and cells were washed an additional two 
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times. 5 x 106 CD4+ CFSE+ OT-II cells were injected into the tail vein of each C57BL/6 
recipients. One day after T cell injection, Ccl17E/+ and Ccl17E/E derived BMDCs were 
pulsed with 1 µg/ml OVA2 peptide for 30 min for MHC class II-restricted T cell 
stimulation. Untreated DCs were used as control. 5 x 106 DCs were applied to recipient 
mice by footpad injection. Three days later, single-cell suspensions were prepared from 
popliteal LNs of recipients and the T cell proliferation was monitored by CFSE dye 
dilution using flow cytometry. 
II.10 Data illustration and statistical analysis  
Graphs display results as mean ± SEM of 3 to 10 independent experiments, if not indicated 
otherwise. To compare data, an unpaired Student’s t-test with Welch’s correction was 
performed using GraphPad Prism 4. Differences with at least P<0.05 were considered as 
statistically significant. 
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III Results 
III.1 CCL17-producing myeloid DCs and the role of this 
chemokine in DC function 
As described before, the thymus and activation-regulated chemokine (TARC/CCL17) is 
produced by DCs belonging to the CD11b+CD8-Dec205+ DC subset, including the myeloid-
related DCs located in various lymphoid and nonlymphoid organs such as thymus, LN, lung, 
and the intestine (Alferink, Lieberam et al. 2003). Using a reporter mouse model, which 
allows tracking of CCL17-expressing cells in vivo by insertion of an eGFP cassette into the 
endogenous murine CCL17 locus, we investigated the role of this chemokine in regulating 
DC-specific functions such as phagocytosis, migration, chemotaxis and T cell activation. 
III.1.1 CCL17+ DCs belong to the most mature myeloid DC 
population 
In line with previous findings (Alferink, Lieberam et al. 2003), detailed FACS analyses of 
pooled peripheral LNs from Ccl17E/+, Ccl17E/E, Ccl17E/+ Apoe-/- and Ccl17E/E Apoe-/- mice 
revealed that CCL17+ cells are exclusively restricted to a subpopulation of CD11c+MHC-
II+CD11b+CD4-CD8a-CD115-F4/80-440c-PDCA-1- DCs, frequently referred to as cDCs. This 
was confirmed in CD11c+ DCs synchronously differentiated by GM-CSF from progenitor 
cells generated from Ccl17E/+ or Ccl17E/E bone marrow. Whereas CCL17 was not detectable 
in undifferentiated progenitor cells as shown in Fig. III.1.1 A on day 2, CCL17+ cells 
appeared concomitantly with surface expression of CD11c after three to four days in culture. 
CCL17+ cells further expanded during differentiation and maturation up to ten days in culture, 
defining a distinct subpopulation of DCs (Fig. III.1.1 A). Compared with EGFP- DCs, EGFP+ 
Ccl17E/+ and EGFP+ Ccl17E/E DCs displayed increased surface expression of the co-
stimulatory molecules CD80, CD86 and CD40 in vitro (Fig. III.1.1 B), indicating a higher 
activation state of EGFP+ DCs. However, we could not observe a significant difference in the 
surface marker expression levels of co-stimulatory molecules when compared EGFP+ 
Ccl17E/+ with EGFP+ Ccl17E/E DCs. Therefore, we concluded that CCL17 expression itself 
does not alter the phenotype of DCs. 
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Fig. III.1.1: Flow cytometry analysis of cultured DCs. A DCs were differentiated from progenitor cells 
generated from bone marrow of Ccl17E/+ or Ccl17E/E mice (II.5.1). EGFP and CD11c expression were assessed at 
indicated time points by FACS analysis (II.7.1); representative dot blots are shown. Quantification of the 
frequencies of CD11c+ and CD11c+CCL17+ DCs among cells generated from Ccl17E/+ bone marrow at the time 
points indicated is shown in the lower panel; n=3. B The expression of co-stimulatory molecules was assessed in 
untreated EGFP- Ccl17E/+ (upper panel), EGFP+ Ccl17E/+ and EGFP+ Ccl17E/E (lower panel) BMDCs by FACS 
analysis; representative histograms are shown, dashed lines indicate controls (FMO/fluorescence minus one). 
Data represent mean±SEM from three independent experiments in duplicate. 
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III.1.2 CCL17 expression does not influence other DC-specific 
genes 
To exclude that CCL17-deficient DCs exhibit additional intrinsic defects, which could have 
an impact on Ag-uptake, Ag-presentation and processing, T cell activation or DC migration 
into secondary lymphoid organs, the expression profile of DC-specific genes, including co-
stimulatory molecules, cytokines and chemokines was compared in cultured and sorted 
EGFP+ Ccl17E/+ versus EGFP+ Ccl17E/E BMDCs by real-time PCR and microarray analysis. 
Using real-time PCR, the expression levels of different chemokine receptors (Ccr2, 
Ccr7, Cxcr2, Cxcr4 and Cxcr6) were analyzed (Fig. III.1.2 A). To have an internal control, 
we also investigated Ccl17 expression levels in both EGFP+ Ccl17E/+ and EGFP+ Ccl17E/E 
BMDCs. Except for Ccl17 transcript levels, which were absent in EGFP+ Ccl17E/E BMDCs as 
expected, only marginal differences in gene expression were observed. Interestingly, Cxcr4 is 
down-regulated during DC maturation. Whereas on day four mRNA expression levels could 
still be detected (data not shown), Cxcr4 was not expressed anymore on day ten of 
differentiation in both EGFP+ Ccl17E/+ and EGFP+ Ccl17E/E BMDCs, indicating that 
monocytes rather than mature DCs express Cxcr4 and that Ccl17-deficiency does not 
influence DC maturation. 
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Fig. III.1.2 A: Real-time PCR analysis of cultured DCs. EGFP+ BMDCs generated from Ccl17E/+ or Ccl17E/E 
mice were harvested on day ten of differentiation. EGFP+ mature DCs were sorted (II.5.4) and analyzed using 
real-time PCR (II.6.2). Data represent mean ± SEM. 
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To further exclude differences in gene expression between EGFP+ Ccl17E/+ and EGFP+ 
Ccl17E/E DCs, an oligo microarray with 270 genes specific for DC maturation and activation 
was performed. Similar to the real-time PCR results, only marginal differences in gene 
expression were observed, except for Ccl17 transcript levels, which were increased in EGFP+ 
Ccl17E/+ BMDCs with a >2-fold difference in intensity over baseline levels (log2>1), (Fig. 
III.1.2 B). 
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Fig. III.1.2 B: Oligo microarray analysis of cultured DCs. EGFP+ mature DCs were sorted and analyzed 
using oligo microarray (II.6.3). For quantification, intensity of signal was subtracted from the local background 
and further normalized via house-keeping genes and negative controls (e.g. blanks) to obtain a relative intensity 
for each spot. These relative intensities were used to compare samples. Except for Ccl17 expression (red circles) 
no significant differences in gene expression were observed. 
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III.1.3 CCL17 does not influence phagocytic ability or DC 
migration 
DCs are specialized in the capture, processing and presentation of Ags to T cells. To 
investigate the influence of CCL17 on Ag-uptake, phagocytosis assays using Di-labeled 
oxLDL as a potential Ag were performed. oxLDL is described to be a possible Ag in 
atherosclerosis (Stemme, Faber et al. 1995). Both differentiated EGFP+ Ccl17E/+ and EGFP+ 
Ccl17E/E DCs phagocytosed Di-labeled oxLDL less efficiently than EGFP- Ccl17E/+ DCs. In 
addition, compared with EGFP- DCs, EGFP+ Ccl17E/+ and EGFP+ Ccl17E/E DCs displayed a 
further up-regulation of co-stimulatory molecules by addition of oxLDL (Fig. III.1.3 A), again 
indicating a higher activation state of EGFP+ DCs with no significant differences between the  
EGFP+ Ccl17E/+ and EGFP+ Ccl17E/E BMDCs. This leads to the conclusion that CCL17 has 
no impact on the ability of cDCs to phagocytose Ag or death cell material, nor does it affect 
the expression of co-stimulatory molecules. 
To further present the captured and processed Ags to naïve T cells in secondary 
lymphoid organs, DCs upregulate the chemokine receptor CCR7 and migrate to the lymphoid 
tissue. To test, if CCL17 influences migration of mature DCs, transwell migration assays were 
performed. EGFP+ Ccl17E/+ DCs compared with EGFP+ Ccl17E/E DCs showed no significant 
difference in random migration or in migration towards the chemokine ELC/CCL19, which is 
the ligand of CCR7 (Fig. III.1.3 B). 
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Fig. III.1.3 : Phagocytotic ability and migration of cultured DCs. A BMDCs were incubated with Di-labeled 
oxLDL (10 µg/ml, 90 min) and its uptake was assessed by FACS analysis (II.8.1); n=3. The expression of co-
stimulatory molecules was assessed in EGFP- Ccl17E/- (upper panel), EGFP+ Ccl17E/+ and EGFP+ Ccl17E/E 
(lower panel) BMDCs after incubation with oxLDL by FACS analysis (II.7.1); representative histograms are 
shown, dashed lines indicate controls (FMO/fluorescence minus one). B Random migration and migration 
towards ELC (50 ng/ml) of Ccl17E/+ or Ccl17E/E BMDCs in transwell chemotaxis chambers (II.8.2) was 
quantified by FACS analysis; n=5. Data represent mean ± SEM. *P<0.05. 
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III.1.4 CCL17 attracts CD4+ T cells 
CCL17 is known to be a chemoattractant for T cells (Lieberam and Forster 1999). To confirm 
that CCL17-producing DCs also attract T cells, in vitro transwell assays and in vivo 
recruitment assays were performed. 
CD4+ T cells were isolated from spleen and LN cells of wt mice and were allowed to 
transmigrate towards sorted EGFP+ Ccl17E/+ and EGFP+ Ccl17E/E BMDCs, which were placed 
in the lower chamber of transwell-migration plates. Transmigrated cells were monitored using 
flow cytometry. We observed that EGFP+ Ccl17E/+ BMDCs induced more chemotaxis of 
CD4+ T cells than EGFP+ Ccl17E/E BMDCs in vitro (Fig. III.1.4 A), indicating that CCL17 
plays a role in CD4+ T cell recruitment by CCL17-expressing DCs. 
To investigate the recruitment of CD4+ T cells via CCL17 in vivo, the air pouch model 
was used. Murine recombinant CCL17 was injected into the air pouch and recruited CD4+ T 
cells were monitored using flow cytometry. PBS injection served as control. Similar to the in 
vitro results, CD4+ T cells were recruited by recombinant CCL17 into air pouches (Fig. III.1.4 
B).  
Chemokines have been suggested to orchestrate T cell recruitment into the LN (von 
Andrian and Mempel 2003). To test, if CCL17 also influences T cell homing into secondary 
lymphoid organs in vivo, homing experiments were performed. CFSE+CD4+ T cells were 
injected into the tail vein of Ccl17E/E Apoe-/- and Ccl17+/+ Apoe-/- mice. Homing of 
CFSE+CD4+ T cells to LNs via high endothelial venules was reduced in Ccl17E/E Apoe-/- as 
compared to Ccl17+/+ Apoe-/- mice four days after transfer (fig. III.1.4 C), which may thus 
again reflect CCL17-dependent differences in T cell recruitment and/or retention. 
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Fig. III.1.4: CD4+ T cell migration towards CCL17. A Migration of CD4+ T cells towards Ccl17E/+ or 
Ccl17E/E BMDCs in transwell chemotaxis chambers (II.8.3) was quantified by FACS analysis; n=5. B The 
recruitment of CD4+ T cells into the air pouch in response to PBS (control) or recombinant mouse CCL17 (20 
ng/ml) was determined by quantifying the numbers of CD4+ T cells by FACS analysis in the lavage fluid after 4 
hours (II.9.4) ; n=3 each. C CD4+ CFSE+ T cell homing was assessed four days after injection into the tail vein 
of Ccl17E/E Apoe-/- compared with Apoe-/- mice. Homing was determined using flow cytometry (II.9.4). Data 
represent mean ± SEM. *P<0.05, **P<0.005. 
 
III.1.5 CCL17 is required for efficient CD4+ T cell priming and 
polarization 
We next investigated the effects of CCL17 on DC-induced T cell proliferation and 
polarization. To this end, CFSE-labeled OT-II T cells were transferred into mice injected with 
sorted, untreated or OVA-2-pulsed EGFP+ Ccl17E/+ or EGFP+ Ccl17E/E DCs differentiated 
from bone marrow progenitor cells. While no T cell proliferative response was observed in 
mice injected with unloaded DCs (control), a strong Ag-specific T cell proliferation was 
induced by OVA-2-pulsed EGFP+ Ccl17E/+ DCs, which by comparison was significantly 
enhanced in response to OVA-2-pulsed EGFP+ Ccl17E/E DCs (Fig. III.1.5 A). To further 
confirm this observation, T cell proliferation assays were performed, using sorted, progenitor 
cell-derived DCs generated from Ccl17E/+ or Ccl17E/E bone marrow and isolated CD4+ OT-II 
T cells from spleen and LNs of wt mice. No T cell proliferative response was observed in 
CD4+ OT-II T cells co-incubated with unpulsed DCs and an only marginal response was 
elicited by OVA-2-pulsed-EGFP- Ccl17E/+ or EGFP- Ccl17E/E DCs. In contrast, OVA-2-
pulsed EGFP+ Ccl17E/+ DCs induced a strong Ag-specific proliferation of CD4+ OT-II T cells, 
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which was even further enhanced in CD4+ OT-II T cells co-incubated with OVA-2-pulsed 
EGFP+ Ccl17E/E DCs, similar as seen in vivo (Fig. III.1.5 B). 
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Fig. III.1.5: CD4+ OT-II T cell proliferation after DC interaction. A Sorted EGFP+ Ccl17E/+ BMDCs 
(untreated control), OVA-2-pulsed EGFP+ Ccl17E/+ or EGFP+ Ccl17E/E BMDCs were transferred into wt mice 
transfused with CFSE+ CD4+ OT-II T cells. After three days, T cell proliferation was quantified by CSFE 
dilution and FACS analysis (II.9.5); representative dot plots are shown; n=6 independent experiments. B Sorted 
untreated or OVA-2-pulsed EGFP-, EGFP+ Ccl17E/+ or EGFP+ Ccl17E/E BMDCs were incubated with CD4+ OT-
II T cells; n=5 independent experiments. T cell proliferation was quantified by CSFE dilution and FACS analysis 
after three days (II.8.4). Data represent mean ± SEM. *P<0.05, **P<0.005. 
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To unravel the polarization pattern and cytokine response elicited by Ag-presenting 
EGFP+ Ccl17E/+ versus EGFP+ Ccl17E/E BMDCs, OT-II CD4+ T cells from the in vitro co-
cultures were back-sorted and subjected to microarray profiling. The transcriptional profile in 
polarized CD4+ OT-II T cells after three days of co-incubation with EGFP+ Ccl17E/+ in 
contrast to EGFP+ Ccl17E/E BMDC subpopulations revealed substantial differences. In 
comparison to control (OT-II CD4+ T cells cultured without DCs), exposure to EGFP+ 
Ccl17E/+ but not EGFP+ Ccl17E/E DCs led to an up-regulation of several transcription factors, 
including NF-kB1, Stat1 and Stat4, Socs1, Socs3, and Gata3, and typical Th1 cytokines such 
as Tnf-α, Il-2 and Ifn-γ but not the Th2 cytokines Il-10 and Il-4 (Fig. III.1.6), indicating that 
EGFP+ Ccl17E/+ DCs prime CD4+ OT-II T cells in a Th1 specific manner.  
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Fig. III.1.6: Oligo microarray analysis of polarized CD4+ OT-II T cells. CD4+ OT-II T cells were back-
sorted, and gene expression assessed by microarray profiling (colour coding for expression: green, low; gray, 
median; red, high) (II.6.3). 
 
To further confirm the results from the microarray and the conclusion that CCL17-
producing DCs prime CD4+ OT-II T cells in a Th1 specific manner, intracellular FACS 
analysis for phosphorylated STAT1, 3 and 6 were performed on back-sorted CD4+ OT-II T 
cells from BMDC co-cultures. STAT1 is activated upon IL-12 and IFN-γ stimulation and 
leads to a Th1 immune response, whereas STAT3 activation leads to Th17 and STAT6 to Th2 
immune responses. FACS analysis revealed an enhanced phosphorylation of the transcription 
factor STAT1 in T cells exposed to EGFP+ Ccl17E/+ DCs compared to T cells co-cultured 
with EGFP+ Ccl17E/E DCs, whereas STAT3 and STAT6 phosphorylation levels were 
unaltered (Fig. III.1.7 A). Moreover, elevated levels of Il-2, Ifn-γ and Il-17, but not, Il-4 and 
Il-10 transcripts were observed from these OT-II T cells (Fig. III.1.7 B), corresponding with a 
higher expression of IL-2, IFN-γ and IL-17 in the supernatants of these T cells compared with 
T cells exposed to EGFP+ Ccl17E/E DCs (Fig. III.1.7 C). This shows that DC-expressed 
CCL17 is required to induce Th1 and Th17 polarization in T cells.  
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Fig. III.1.5: Cytokine and pSTAT analysis of CD4+ T cells after DC interaction. A Sorted CD4+ OT-II T 
cells cultured with OVA-2-pulsed EGFP+ Ccl17E/+ or EGFP+ Ccl17E/E BMDCs for three days were subjected to 
intracellular stainings for phosphorylated STATs (II.7.1). Representative histograms are shown; inserted 
numbers indicate MFI. B OT-II T cells were back-sorted, and gene expression assessed by real-time PCR-
analysis (II.6.2). C Protein concentrations in supernatants were analyzed by cytometric bead array; n.d. not 
detectable (II.7.2). Data represent mean ± SEM. *P<0.05, **P<0.005, ***P<0.0005. 
 
In addition, to investigate the direct influence of CCL17 on T cell activation and 
polarization, CCL17 was either blocked with a blocking Ab against CCL17 or added in form 
of a recombinant CCL17 protein. We observed that Ab blockade of CCL17 enhanced CD4+ 
OT-II T cell proliferation and inhibited the secretion of IFN-γ mediated by EGFP+ Ccl17E/+ 
DCs (Fig. III.1.8 A). This was reflective of the results from the T cell proliferation assays 
using EGFP+ Ccl17E/E BMDCs. Conversely, addition of recombinant CCL17 to co-cultures of 
EGFP+ Ccl17E/E DCs and CD4+ OT-II T cells reversed the increase in Ag-specific T cell 
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proliferation and promoted IFN-γ secretion as seen in proliferation studies with EGFP+ 
Ccl17E/+ BMDCs (Fig. III.1.8 B). 
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Fig. III.1.8: Influence of CCL17 concerning CD4+ T cell priming and polarization. A Sorted OVA-2-pulsed 
EGFP+Ccl17E/+ or EGFP+ Ccl17E/E BMDCs were incubated with CD4+ OT-II T cells in the presence of a 
blocking Ab to CCL17 (10 µg/mL), or B recombinant CCL17 (20 ng/mL); n=6 independent experiments. T cell 
proliferation was quantified by CSFE dilution and FACS analysis after three days (II.8.4) and IFN-γ 
concentrations were analyzed in supernatants by cytometric bead array (II.7.2). Data represent mean ± SEM. 
*P<0.05. 
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III.2 Involvement of DC-derived CCL17 in atherosclerosis 
A network of DCs has been identified in the arterial intima of healthy young individuals 
(Millonig, Niederegger et al. 2001) and an accumulation of DCs can be observed in the intima 
and adventitia of atherosclerosis-susceptible regions in mice (Jongstra-Bilen, Haidari et al. 
2006; Liu, Yu et al. 2008). In advanced human plaques, increased numbers of DCs are found 
within rupture-prone regions in clusters with T cells (Yilmaz, Lochno et al. 2004; Bobryshev 
2005). Moreover, DC-derived chemokines, such as CCL17 are expressed in atherosclerotic 
lesions (Greaves, Hakkinen et al. 2001), but the role of CCL17 was not further investigated 
yet. Using the Ccl17 EGFP reporter mouse crossed into Apoe-/- background, we investigated 
the role of DC-derived CCL17 in atherogenesis. 
 
III.2.1 CCL17-expressing DCs are not located within the vessel 
wall of healthy mice 
Using immunofluorescence and multiphoton microscopy, we frequently detected EYFP+ cells 
in the intima and adventitia of the aorta and aortic root and within cardiac valves of healthy 
CD11c-EYFP reporter mice (Fig. III.2.1 A). By using flow cytometry, CD11c+ cells could 
also be detected in enzymatically digested aortas of healthy wt mice (0.3±0.1% CD11c+ cells 
of total cells). This network of CD11c+ cells showed a prominent staining for MHC-II 
assessed by multiphoton microscopy (Fig. III.2.1 A). Whereas mature DCs were found to 
produce CCL17 in Ccl17E/+ mice and can be visualized by their expression of EGFP in 
various lymphoid and nonlymphoid organs (Alferink, Lieberam et al. 2003) (Fig. III.2.1 B), 
we detected almost no EGFP+ cells in the aortic intima or adventitia of naïve mice (Fig. III.2.1 
C). 
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Fig. III.2.1: Imaging of CD11c+ and CCL17+ DCs in healthy vessels. A The network of EYFP+CD11c+ DCs 
(green) can be detected by immunofluorescence (II.7.5) in the aortic root (left two panels) and by multiphoton 
microscopy (II.7.6) in the en face prepared aorta (middle right panel) of a CD11c-EYFP reporter mouse; 
representative maximum intensity projection of a 30 µm thick volume is shown. Multiphoton microscopy 
staining for MHC-II+ (red) in the en face prepared aorta of a wt mouse; collagen was visualized by second 
harmonic generation (SHG, blue, far right panel). B EGFP+ DCs (green) can be frequently detected in 
perifollicular regions of LNs of naïve Ccl17+/E Apoe-/- mice, as assessed by immunofluorescence microscopy; 
cell nuclei were counter-stained by DAPI (blue). C EGFP+ DCs (green) can hardly be detected in the aortic roots 
of naïve Ccl17+/E Apoe-/- and Ccl17E/E Apoe-/- mice using immunofluorescence microscopy. Cell nuclei were 
counter-stained by DAPI (blue). 
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III.2.2 CCL17-expressing DCs accumulate in atherosclerotic 
lesions 
To further elucidate, if CCL17-expressing DCs are located in atherosclerotic lesions in 
contrast to naïve vessels, real-time PCR analysis, flow cytometry, immunofluorescence 
microscopy and multiphoton microscopy were performed.  
By using real-time PCR, we observed an increase in CCL17 mRNA expression in 
human carotid endartherectomy specimen compared with macroscopically healthy carotid 
arteries (13.7±3.5 fold increase, n=3, P<0.005). Ccl17 transcripts were also increased in 
advanced atherosclerotic aortas of Apoe-/- mice given a high-fat diet (3.8±0.8-fold increase 
over healthy aortas, n=4, P<0.01) (Fig. III.2.2 A). In support of previous findings (Greaves, 
Hakkinen et al. 2001), an increased frequency of CD11c+ cells was evident in the aorta of 
Apoe-/- mice fed a high-fat diet as compared to healthy vessels and CD11c+EGFP+ DCs were 
increased in aortic lesions of Ccl17E/+ Apoe-/- or Ccl17E/E Apoe-/- mice with diet-induced 
atherosclerosis, as determined by FACS analysis of digested aortas (Fig. III.2.2 B). This result 
was confirmed using immunofluorescence (Fig. III.2.2 C) and multiphoton microscopy of 
aortic roots with diet-induced and spontaneous lesions (Fig. III.2.2 D). Whereas DCs present 
in large arteries express little CCL17 under steady-state conditions, our data thus indicate that 
CCL17+CD11c+ DCs accumulate in atherosclerotic arteries. We observed no difference in the 
numbers of EGFP+ DCs in Ccl17E/+ Apoe-/- compared with Ccl17E/E Apoe-/- mice. 
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Fig. III.2.2: CCL17+ DCs in atherosclerotic lesions. A CCL17 transcription levels in healthy vessels compared 
with atherosclerotic vessels were assessed using real-time PCR analysis (II.6.2). n=5 independent experiments; 
data represent mean ± SEM, **P<0.005. B Quantification of EGFP+CD11c+ DCs in aortas of naïve Ccl17E/+ 
Apoe-/- and Ccl17E/E Apoe-/- mice or after high-fat diet feeding, using enzymatic digestion (II.5.2) and FACS 
analysis; representative dot blots and percentages within quadrants are shown; n=6; data represent mean ± SEM, 
***p<0.0001. C EGFP+ DCs (green, indicated by arrows) in the aortic root of Ccl17E/+ Apoe-/- and Ccl17E/E Apoe-
/-
 mice after 12 weeks of high-fat diet (upper panels) and after 6 months of normal chow (lower panels); cell 
nuclei are counter-stained by DAPI (blue). D Maximum intensity projection of a z-stack (left) and high 
magnification z-slice (right) with EGFP+ DCs (green, indicated by arrows) in the atherosclerotic aortic root of a 
Ccl17E/+ Apoe-/- mouse on normal chow; collagen is visible due to SHG (blue), nuclei are counter-stained with 
propidium iodide (red). 
 
III.2.3 Deficiency of CCL17 reduces atherosclerosis in Apoe-/- 
mice 
We next investigated the role of CCL17+ DCs in atherosclerotic lesion formation in aortic 
roots and in thoracabdominal aortas in Ccl17+/+ Apoe-/- and Ccl17E/E Apoe-/- mice. After six 
months of normal chow, a marked reduction in atherosclerotic plaque formation was observed 
in Ccl17E/E Apoe-/- mice in comparison to Ccl17+/+ Apoe-/- mice (Fig. III.2.3 A), as visible after 
Oil-red-O staining, while no alterations in lipid levels were observed (Table III.1). 
Quantitative immunostaining revealed that the reduction of plaque area was associated with a 
significant decrease in the relative content of macrophages (Fig. III.2.3 B), whereas the 
relative content of SMCs was significantly increased in Ccl17E/E Apoe-/- mice when compared 
to Ccl17+/+ Apoe-/- mice (9.0±2.0% vs 1.9±0.6% smoothelin+ plaque area, P<0.005, data not 
shown), indicating a shift towards a more stable plaque phenotype in Ccl17E/E Apoe-/- mice. 
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Although the frequency of lesional EGFP+ DCs did not differ (data not shown), a significant 
reduction in the number of CD3+ T cells was observed in Ccl17E/E Apoe-/- mice (Fig. III.2.3 
C), implying a role of lesional CCL17 in the attraction of T cells to sites of plaque 
development. 
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Fig. III.2.3: The effect of CCL17-deficiency in 6 months old mice. A Atherosclerotic lesions were quantified 
in the aortic root and thoracoabdominal aorta after staining with oil-red-O in Ccl17+/+ Apoe-/- and Ccl17E/E Apoe-/- 
mice on normal chow for 6 months (II.7.4); representative images of the aortic root and the thoracoabdominal 
aorta are shown. The relative frequency of B MOMA-2+ macrophages and C CD3+ T cells per plaque area were 
determined by quantitative immunofluorescence (II.7.5). Data represent mean±SEM. *P<0.05, **P<0.005. 
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LDL indicates low-densitiy lipoprotein
HDL indicates high-density lipoprotein
87.4 ± 10.1
83.5 ± 13.9
213.9 ± 91.7
100.4 ± 17.0
103.6 ± 17.6
98.7 ± 11.2
67.0 ± 10.0
85.6 ± 10.7
140.8 ± 16.3
172.5 ± 21.6
338.4 ± 11.3
273.0 ± 30.7
125.2 ± 21.4
128.9 ± 14.6
99.8  ± 3.6
88.4  ± 2.3
226.8 ± 21.3
256.0 ± 24.9
558.0 ± 41.8
487.0 ± 37.6
410.8 ± 35.1
417.1 ± 14.9
521.2 ± 63.4
442.3 ± 44.6
353.7 ± 31.6
386.5 ± 30.7
839.3 ± 67.2
621.0 ± 51.2
600.1 ± 61.0
662.3 ± 28.8
713.3 ± 92.8
604.0 ± 57.2
no diet
Apoe-/-
Apoe-/-Ccl17E/E
Western diet, 12 weeks
Apoe-/-
Apoe-/-Ccl17E/E
Western diet, 24 weeks
(12 weeks for and after 
transplantation)
Apoe-/-
Apoe-/-Ccl17E/E
T cell injection
+ Apoe-/- CD4+ T cells
+ Apoe-/- Ccl17E/E CD4+ T cells
Triglyceride,
mg/dL
HDL,
mg/dL
LDL,
mg/dL
Total 
Cholesterol,
mg/dL
Genotypes on different diets
Mouse Serum Lipid Content
 
Table III.1: Serum cholesterol and triglyceride levels of different atherosclerotic mouse models. 
 
 
Similarly, lesion formation was reduced in the aortic root and aorta of Ccl17E/E versus 
Ccl17+/+ Apoe-/- mice after 12 weeks of feeding a high-fat diet. Again, no alterations in lipid 
levels were observed (Fig. III.2.4, Table III.1). 
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Fig III.2.4: The effect of CCL17-deficiency in mice fed a high fat diet. Atherosclerotic lesions were 
quantified in the aortic root and thoracoabdominal aorta after staining with oil-red-O in Ccl17+/+ Apoe-/- and 
Ccl17E/E Apoe-/- mice receiving a high fat diet for 12 weeks (II.7.4); representative images of the aortic root and 
the thoracoabdominal aorta are shown. Data represent mean±SEM. *P<0.05. 
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III.2.4 CCL17 contributes to lesion progression in Apoe-/- mice 
To further dissect a contribution of CCL17 to lesion progression, Apoe-/- mice bearing 
established atherosclerotic lesions after 12 weeks of high-fat diet feeding were lethally 
irradiated and reconstituted with Ccl17+/+ Apoe-/- or Ccl17E/E Apoe-/- bone marrow and 
continued on an high-fat diet for another 12 weeks. In mice receiving Ccl17E/E Apoe-/- bone 
marrow (Ccl17E/E Apoe-/- → Apoe-/-), lesion progression was significantly delayed in the aortic 
root and completely prevented in the thoracoabdominal aorta after an additional 12 weeks of 
high-fat diet compared to recipients of Ccl17+/+ Apoe-/- bone marrow (Ccl17+/+ Apoe-/- → 
Apoe-/-), while no alterations in lipid levels were observed (Fig. III.2.5 A, Table III.1). As with 
somatic Ccl17 deficiency, the content of macrophages in the plaque was diminished and the 
number of CD3+ T cells was significantly reduced in Ccl17E/E Apoe-/- → Apoe-/- chimeric mice 
in contrast to Ccl17+/+ Apoe-/- → Apoe-/-chimeric mice (Fig. III.2.5 B and C), recapitulating 
the plaque phenotype found at earlier lesion stages. In addition, EGFP+ CCL17+ DCs became 
detectable in advanced plaques in the aortic root, the adventitia and in LNs of chimeric Apoe-/- 
mice transplanted with Ccl17E/+ Apoe-/- bone marrow. This suggests a continuous influx of 
BMDCs during lesion progression (Fig. III.2.5 D). 
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Fig. III.2.5: The role of Ccl17 deficiency in atheroprogression in Apoe-/- mice with established lesions. A 
Apoe-/- mice fed a high-fat diet for 12 weeks were transplanted with either Ccl17+/+ Apoe-/- (Ccl17+/+ → Apoe-/-) 
or Ccl17E/E Apoe-/- bone marrow (Ccl17E/E → Apoe-/-) (II.9.2). After an additional 12 weeks of high-fat diet, 
atherosclerotic lesions were quantified in the aortic root and thoracoabdominal aorta after staining with oil-red-O 
(II.7.4); representative images are shown. The frequency of B MOMA-2+ macrophages and C CD3+ T cells per 
plaque area were determined by quantitative immunofluorescence (II.7.5). Data represent mean ± SEM. n.s., not 
significant. *P<0.05, ***P<0.0005. D EGFP+ DCs accumulate in the atherosclerotic lesion of the aortic root and 
in the adventitia in chimeric Ccl17+/E Apoe-/- → Apoe-/- mice 12 weeks after bone marrow reconstitution and 
high-fat diet feeding. Representative images are shown. 
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III.2.5 Vascular DCs home to lymphoid organs 
After Ag-uptake, peripheral DCs migrate to draining LNs to present the Ag to the according T 
cells. To investigate whether also vascular DCs home to lymphoid organs, DCs were sorted 
after isolation and digestion of the aorta from naïve CD11c-EYFP mice and injected into the 
footpad of Apoe-/- mice. 18 h after injection, vascular CD11c+ DCs could indeed be detected 
in the popliteal LN of the recipient mice (Fig. III.2.6 A). To scrutinize whether these 
mechanisms also apply and possibly underlie the atheroprotective effects of the CCL17-
deficiency in vivo, EGFP+ Ccl17E/+ and EFGP+ Ccl17E/E BMDCs were sorted and injected 
into the footpad of Apoe-/- recipient mice. Both BMDCs similarly homed to regional LNs 18 
hours after transfer, with no significant difference in all numbers between the two 
subpopulations in the LNs (Fig. III.2.6 B). This thus confirms our previous in vitro data on 
DC migration (Fig. III.1.3) and indicates that deficiency of CCL17 does not influence the 
migration of these BMDCs. 
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Fig. III.2.6 Homing of vascular and cultured DCs into LNs. A EYFP+CD11c+ DCs sorted from digested 
aortas of naïve CD11c-EYFP-mice were injected into the footpad of Apoe-/- mice (II.9.4). After 18 h, the 
presence of EYFP+ cells was analyzed in the popliteal LN by FACS analysis. Representative dot plots are 
shown. B EGFP+ Ccl17E/+ and EGFP+ Ccl17E/E BMDCs (green) in popliteal LNs of Apoe-/- mice 18 h after 
footpad injection. Representative images are shown. 
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III.2.6 T cells primed by CCL17+ DCs mediate atherogenesis 
We next evaluated whether the changes in the T cell cytokine profile in vitro (Fig. III.1.6 and 
Fig. III.1.7) also occured in vivo. Real-time PCR analyses of LN cells collected from Ccl17E/E 
Apoe-/- mice on high-fat diet for 12 weeks displayed diminished Il-2, Ifn-γ and Il-17 mRNA 
levels, but higher Il-4 and Il-10 mRNA levels relative to LN cells from Ccl17+/+ Apoe-/- mice 
(Fig. III.2.7 A). Given the preferential localization of CCL17+ DCs at sites of inflammation 
and the LN, these finding suggest that CCL17+ DCs are of pivotal importance in determining 
atherogenic immune responses in T cells. To further investigate the type of T cell response, 
ELISAs of the blood sera were performed. Notably, serum levels of IgG1 Abs to 
malondialdehyde-modified LDL were elevated in Ccl17E/E Apoe-/- versus Ccl17+/+ Apoe-/- 
mice fed a high-fat diet (Fig. III.2.7 B). This could be due to the enhanced IL-4 expression, 
providing B cell help for Ab production, indicating a Th2 phenotype in Ccl17-deficient mice. 
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Fig. III.2.7: Cytokine and antibody analysisi of atherosclerotic mice. A mRNA expression was analyzed by 
real-time PCR in LN cells collected from Ccl17+/+ Apoe-/- and Ccl17E/E Apoe-/- mice fed a high-fat diet for 12 
weeks (II.6.2); n=4 independent experiments. B Specific IgG1 antibody titers to MDA-LDL in the sera of 
Ccl17+/+ Apoe-/- and Ccl17E/E Apoe-/- mice fed a high fat diet over 12 weeks were determined by ELISA (II.7.3). 
Data are presented as relative light units (RLU) / 100 ms. Data represent mean±SEM. *P<0.05, P**<0.005. 
 
To rigorously address the effects of a CCL17-polarized T cell help on atherosclerosis 
development, CD4+ T cells were sorted from 6 months-old Ccl17+/+ Apoe-/- and Ccl17E/E 
Apoe-/- mice and adoptively transferred into 8 week-old Apoe-/- mice depleted from CD4+ 
cells. After 6 weeks of high-fat diet, atherosclerotic plaque formation was markedly 
attenuated in mice repopulated with CD4+ T cells from Ccl17E/E Apoe-/- mice, as compared to 
those receiving CD4+ T cells from Ccl17+/+ Apoe-/- mice. This was associated with a 
significant decrease in the relative plaque macrophage content (Fig. III.2.8 A and B), while no 
alterations in lipid levels were observed (Table III.1). Confirming the previously observed 
differences in T cell polarization, LN cells from Apoe-/- mice repopulated with T cells from 
Ccl17E/E Apoe-/- mice displayed a significant down-regulation of Ifn-γ and Il-17 transcripts, 
whereas no differences were seen for Il-4, Il-10 and Foxp3 (Fig. III.2.8 C). Taken together, 
these data establish that the effector functions exerted by CCL17+ DCs are central in the 
initiation of Th1 and Th17 polarized cell responses and thereby mechanistically determine the 
development of atherosclerotic lesions. 
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Fig. III.2.8: T cells primed by CCL17+ DCs mediate atherogenesis. A CD4+ T cells sorted from 6 months-old 
Ccl17+/+ Apoe-/- and Ccl17E/E Apoe-/- mice on normal chow were adoptively transferred into 8 week-old Apoe-/- 
mice depleted from CD4+ cells (II.9.3). After 6 weeks of atherogenic diet, atherosclerotic lesions were quantified 
in the aortic root and thoracoabdominal aorta after staining with oil-red-O (II.7.4); representative images are 
shown B The relative frequency of MOMA-2+ macrophages per plaque area was determined by quantitative 
immunofluorescence (II.7.5) C mRNA expression was analyzed by real-time PCR in LN cells (II.6.2). Data 
represent mean ± SEM. *P<0.05, P**<0.005. 
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IV Discussion 
IV.1 CCL17+ DCs are mature and recruit CD4+ T cells 
DCs fulfill an important regulatory function at the interface of the innate and the adaptive 
immune system. It has previously been reported that CCL17 is produced by DCs in mice. 
Using a fluorescence-based in vivo reporter system, Alferink et al. showed that CCL17 
expression in mice is found in activated Langerhans cells and mature DCs located in various 
lymphoid and nonlymphoid organs, and that the DC-derived chemokine CCL17 is up-
regulated after stimulation with Toll-like receptor ligands (e.g. LPS). 
By using the same fluorescence-based reporter model, we showed that the expression of 
CCL17 defines a subpopulation of CD11c+MHC-II+CD11b+CD4-CD8a-CD115-F4/80-440c-
PDCA-1- DCs, frequently referred to as cDCs, in line with previous findings (Lieberam and 
Forster 1999; Alferink, Lieberam et al. 2003). By generating myeloid CD11c+CD11b+ DCs 
from bone marrow progenitors of Ccl17E/+ or Ccl17E/E mice by adding GM-CSF, CCL17-
producing BMDCs were detected after ten days of differentiation and maturation in culture. 
This DC subtype represents a mature DC subset as shown by FACS analysis of the co-
stimulatory molecules CD80, CD86 and CD40. As compared with EGFP- BMDCs, co-
stimulatory molecules were up-regulated with no significant difference between EGFP+ 
Ccl17E/+ or EGFP+ Ccl17E/E BMDCs. This finding is consistent with the results from 
phagocytosis and migration assays, which confirmed that EGFP+ BMDCs belong to the most 
mature DC population by showing a diminished phagocytotic capability when compared with 
EGFP- BMDCs. 
Chemotactic attraction of T lymphocytes by DCs is mediated through various 
constitutive and inducible chemokines. It has been shown that recombinant murine CCL17 
induced migration of primed ovalbumin-specific CD4+ T cells with a preference for Th2 cells 
during the early phase of the T cell response. These observations suggested that recombinant 
CCL17 directs migration of Ag-experienced Th cells to DCs in lymphoid as well as in 
nonlymphoid organs (Lieberam and Forster 1999) to initiate T cell proliferation and 
differentiation. In this study, we showed that naïve CD4+ T cells are recruited to CCL17-
producing BMDCs in transwell-assays in vitro and towards recombinant CCL17 in vivo using 
the air pouch inflammation model. 
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In the LN, chemokines have been implicated in attracting and engaging T cells for 
direct interactions (von Andrian and Mempel 2003). For T lymphocytes to enter LNs via high 
endothelial venules (HEVs), integrins (e.g. LFA-1) on naïve and memory T cells must be 
activated (Hamann, Jablonski-Westrich et al. 1988; Andrew, Spellberg et al. 1998; Warnock, 
Askari et al. 1998). This process is mediated by the chemokine CCL21 (Stein, Rot et al. 
2000), which is constitutively expressed by high endothelial cells and binds to CCR7 
(Campbell, Bowman et al. 1998; Campbell, Hedrick et al. 1998). CCL19, which is also a 
CCR7 agonist, is expressed by the lymphatic endothelium and interstitial cells in LNs, but not 
by HEVs. Perivascular CCL19 can be transported to the luminal surface of HEVs and induce 
integrin activation on rolling T cells (Baekkevold, Yamanaka et al. 2001). For CCL17, such a 
mechanism in T lymphocyte rolling and arrest has not been investigated so far. However, in 
this study, we showed that reduced numbers of CFSE+ CD4+ T cells isolated from wt mice 
home to LNs of Ccl17E/EApoe-/- mice after adoptive transfer of T cells as compared to 
recipient Ccl17+/+Apoe-/- mice, speculating that CCL17 might also play a role in integrin 
activation on CD4+ T cells and therefore might play a role in T cell homing. It remains to be 
resolved, however, if CCL17 influences integrin activation on rolling T lymphocytes and 
therefore plays a role in T cell recruitment into secondary lymphoid organs. 
 
 
IV.2 CCL17 is required for efficient T cell activation 
T cell activation requires stable and prolonged interactions with DCs (Mempel, Henrickson et 
al. 2004), allowing T cells to organize a mature immunological synapse and integrate TCR 
and co-stimulatory signals (Imai, Baba et al. 1997; Reiter and Pfeffer 2002), which are 
converted into cell-intrinsic changes and epigenetic processes that help to regulate Th1, Th2 
and Th17 cell lineage fate and function by affecting gene transcription. Transient TCR 
stimulation may be sufficient to trigger T cell proliferation but fails to initiate their 
differentiation (Mempel, Henrickson et al. 2004). During early T cell activation, in response 
to signals through the TCR and co-stimulatory molecules, IL-2 is induced in T cells to 
activate STAT5 and entry into the cell cycle in response to signals through the TCR and co- 
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stimulatory molecules, while the cytokine milieu and downstream transcription factor 
networks then determine Th cell lineage choices (Wilson, Rowell et al. 2009). Interestingly, 
the proliferative response was enhanced in T cells interacting with EGFP+ Ccl17E/E DCs 
compared to EGFP+ Ccl17E/+ DCs, whereas their IL-2 expression was decreased, suggesting 
that a prolonged and efficient activation of T cells requires CCL17. 
It has been discussed that chemokine signals may aid in the arrest of T cells on DCs and 
may thus determine the duration of T cell-DC interactions and in addition modulate T cell 
responses. For instance, the chemokine CCL21 was shown to bind to the surface of DCs. This 
binding triggers an Ag-independent chemokine-‘tethered’ adhesion of T cells, which induces 
subsequent TCR signaling and synapse formation and stimulates their proliferation driving a 
Th1 polarization (Friedman, Jacobelli et al. 2006). Moreover, CCR5, CCR7 and CXCR4 
ligands were demonstrated to ‘co-stimulate’ T cell activation in proliferation assays, while the 
receptors CCR5 and CXCR4 on T cells were shown to be recruited to the immunological 
synapse during T cell activation, leading to more stable T cell-DC conjugates and enhanced T 
cell activation (Molon, Gri et al. 2005). The CCL17 chemokine receptor CCR4 has been 
shown to attend to Ag-specific TCR signaling (Bromley, Peterson et al. 2000), and might be 
important in mediating T cell-DC clusters, in line with findings showing mainly CD4+ CCR4+ 
T cells in clusters with DCs in inflamed skin (Katou, Ohtani et al. 2001). In addition, 
exogenous stimulation with CCL17 mediated the adhesion of T cells to DCs (Friedman, 
Jacobelli et al. 2006), in line with our findings that the addition of recombinant CCL17 
reduced Ag-specific T cell proliferation responses and that Ccl17E/E DCs pulsed with 
exogenous recombinant CCL17 triggered an even decreased T cell proliferation. If the 
addition of recombinant CCL17 also leads to a higher secretion of IL-2, and therefore a higher 
state of activation, needs to be further investigated. 
This event of strong DC-T cell adhesion via DC-derived chemokines and their 
chemokine receptors may involve the sensitization of T cells to defined cytokines or the site 
specific recruitment of receptors at the DC-T cell interface, as reported for the TCR, IFN-γR, 
IL-2R and other receptors to induce Th1 cell differentiation (Lee, Turner et al. 2009). 
However, intrinsic defects in Ccl17-deficient DCs are unlikely in this context and can not 
explain the enhanced T cell proliferation after interaction with Ccl17-deficient BMDCs, 
because no changes in the expression of co-stimulatory molecules, cytokines and chemokines  
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were identified by microarray profiling of EGFP+ Ccl17E/+ versus Ccl17E/E BMDCs. It is 
conceivable that CCL17 may contribute to the scanning and integration process, which may 
allow for more thorough interactions of T cells and DCs (Reiter and Pfeffer 2002) so that 
prolonged dwell times may cause the accumulation and retention of CD4+ T cells in CCL17-
expressing LNs. 
 
 
IV.3 CCL17 is required for efficient T cell priming and 
polarization 
Th1 cell development is initiated by STAT1, which together with TCR-triggered transcription 
factors induce the transcripton factors T-bet and STAT4 via IL-12R activation. T-bet, STAT4 
and transcripton factors then mediate the expression and the release of IFN-γ, which in turn 
reinforces the Th1 commitment by activating STAT1 in a positive feedback loop. Th1 lineage 
differentiation is further consolidated by T-bet repressing IL-4 expression to inhibit Th2 cell 
differentiation and by opposing inhibitory effects of GATA-3 on Th1 differentiation (Wilson, 
Rowell et al. 2009). In this study, a Th1 cell lineage commitment in CD4+ T cells interacting 
with CCL17+ DCs in vitro was reflected by an up-regulation of Stat1, Stat4 and Ifn-γ, whereas 
the Th2-related Stat6 transcription factor and Il-10 and Il-4 cytokines were unaltered. In 
addition, STAT6 phosphorylation was unchanged, therefore the initiation of a Th2 cell 
differentiation and subtype stabilization together with IL-4 by binding to and activating 
GATA-3 was inhibited (Wilson, Rowell et al. 2009). Interestingly, although the transcription 
factors involved in Th1 and Th2 differentiation are not required for Th17 cell differentiation 
and can even antagonize this process (Wilson, Rowell et al. 2009), we observed soluble IL-17 
in the supernatants of T cells interacting with EGFP+ Ccl17E/+ but not EGFP+ Ccl17E/E 
BMDCs, in addition to increased Il-17-transcript levels in these T cells. Th17 cell 
differentiation and IL-17 secretion is promoted by TGF-β in the presence of IL-6, which is 
known to activate STAT3 and ROR-γt while inhibiting FOXP3 and regulatory T cell 
differentiation (Wilson, Rowell et al. 2009). In support of a Th17 differentiation above a Treg 
polarization, no changes in the expression of Foxp3 were observed in proliferating T cells 
interacting with EGFP+ Ccl17E/+ DCs and EGFP+ Ccl17E/E DCs. It remains to be resolved,  
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however, if IFN-γ and IL-17 are secreted by simultaneously differentiating Th1 and Th17 
cells, respectively, or might be expressed by the same cell, as described for IFN-γ-producing 
Th17 cells. In these cells, generated upon incubation with IL-12 and IL-23, IFN-γ production 
is mediated through STAT4 and T-bet signaling (Lee, Turner et al. 2009). That this 
subpopulation might also be present among T cells interacting with EGFP+ Ccl17E/+ DCs is 
supported by findings showing that IL-12 is indeed strongly expressed by CCL17+ DCs and 
upregulated upon stimulation (Alferink, Lieberam et al. 2003). 
 
 
IV.4 Involvement of DC-derived CCL17 in atherosclerosis 
A potential involvement and function of DCs in atherosclerosis has remained elusive to date. 
Efforts at depleting this cell population for longer time periods, e.g. in mice carrying a 
transgene to express the diphtheria toxin receptor under the control of CD11c, have proven 
difficult and useless due to the development of a myeloproliferative disorder (Birnberg, Bar-
On et al. 2008). Notably, DC-specific effector functions have not yet been targeted. Here we 
made use of mice deficient in the chemokine CCL17, which is almost exclusively expressed 
as an important effector molecule in a subset of mature cDCs. As mentioned before, these 
mice carry either EGFP for detecting CCL17+ DCs or EGFP in replacement of Ccl17 to study 
the influence of CCL17 on DC function. In addition, these mice were crossed into an Apoe-/- 
background to address the role of this chemokine in atherosclerosis. 
Whereas a CD11c+ DC network could be identified in the intima and adventitia of naïve 
mice, these cells did not produce CCL17. In advanced human plaques, the number of mature 
myeloid DCs and their precursors were increased compared with early lesions and were 
arrayed in clusters with T cells, primarily localizing to the exposed plaque shoulder and 
rupture-prone regions (Yilmaz, Lochno et al. 2004; Bobryshev 2005). In line with this, we 
could observe an increased frequency of lesional CD11c+ DCs during atherosclerotic 
development in mice, and also EGFP+ CD11c+ DCs could be observed in the aortic root of 
Ccl17E/+ Apoe-/- and Ccl17E/E Apoe-/- mice upon lesion progression. Although CCL17 is 
required to sensitize DCs for CCR7-dependent emigration from the skin in atopic dermatitis  
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(I. F. et al., unpublished data, 2009), which might translate to migratory defects of Ccl17E/E 
DCs, no substantial differences in EGFP+ DC accumulation were observed in atherosclerotic 
arteries of Ccl17E/EApoe-/- mice in comparison to Ccl17E/+Apoe-/- mice. In addition, CCL17 
transcripts were up-regulated in human carotid endatherectomy specimen as compared to 
macroscopically healthy arteries, in accordance with findings showing the presence of CCL17 
and increased numbers of myeloid DCs in advanced human plaques (Greaves, Hakkinen et al. 
2001; Yilmaz, Lochno et al. 2004; Bobryshev 2005). An increased EGFP expression was also 
observed in advanced lesions of Ccl17E/+ Apoe-/- → Apoe-/- and Ccl17E/E Apoe-/- → Apoe-/- 
bone marrow-transplanted mice, indicating a continuous influx of EGFP+ DCs into peripheral 
sites of inflammation as atherosclerotic lesions. Of note, while lesional DCs were shown to 
originate from bone marrow-derived monocytes (Jongstra-Bilen, Haidari et al. 2006), we 
similarly observed that EGFP+ DCs derived from transplanted Ccl17E/+ Apoe-/- bone marrow 
accumulated in atherosclerotic carotid arteries, suggesting that circulating bone marrow-
derived DCs can be recruited to lesions during progression and differentiate into CCL17+ 
DCs. The origin or precursors of these cells remains to be clarified. 
Strikingly, also the progression of established lesions in Apoe-/- mice was halted by 
transplantation with Ccl17E/E Apoe-/- bone marrow, indicating that CCL17-dependent 
mechanisms are required to maintain atherogenic immune responses at later stages. This 
might be related to the potential function of lesional CCL17+ DCs to recruit T cells to sites of 
lesion growth to sustain pro-inflammatory immune responses. Here we indeed show that 
despite an enhanced T cell expansion in the absence of CCL17 in vitro, a significant reduction 
of CD3+ T cell numbers was observed in atherosclerotic lesions of Ccl17E/E Apoe-/- mice, 
indicating a prominent role of CCL17 in attracting or retaining T cells at sites of 
inflammation. Whether this mainly involves naïve T cells or Ag-experienced Th1 and Th2 
cells remains to be elucidated, although the observation that CCL17 is able to attract 
effector/memory Th1 and Th2 cells, favors the latter (Andrew, Ruffing et al. 2001; Alferink, 
Lieberam et al. 2003; Freeman, Stolberg et al. 2006). Also the precise mechanisms of 
CCL17-mediated T cell recruitment and retention remain unclear. In conjunction with 
different pro-adhesive molecules expressed in plaques (Zernecke, Shagdarsuren et al. 2008), 
it is conceivable that CCL17 immobilized and presented by endothelial cells (D'Ambrosio, 
Albanesi et al. 2002) may participate in the recruitment of circulating T cells to 
atherosclerotic lesions. In this way, CCL17 might induce rapid integrin-dependent arrest of  
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memory T cells to the cell-adhesion molecule ICAM-1 as has been shown for the integrin-
dependent arrest of memory T cells to ICAM-1 in chronically inflamed skin (Campbell, 
Haraldsen et al. 1999), CCL17-secreting cDCs within atherosclerotic lesions might in this 
way thus contribute to the recruitment of T cells to lesions from the blood stream. Within the 
lesion, T cells exert a net pro-atherogenic effect in hyperlipidemic mice (Zhou, Nicoletti et al. 
2000), but the exact mechanisms are only incompletely understood (further discussed in 
IV.5). 
In addition to lesional CCL17+ DCs, the progression of atherosclerosis might be 
influenced by CCL17+ DCs in secondary lymphoid organs. It is possible that vascular DCs, 
after peripheral acquisition and processing of Ag as circulating lipids, migrate from the vessel 
wall to secondary lymphatic tissue, where they interact with and prime T cells. Here we 
provide evidence that both CD11c+ DCs as CCL17+ DCs from large blood vessels have the 
capacity to migrate to regional LNs after footpad injection. Furthermore, CCL17-expressing 
cells can be also found in large numbers in perifollicular T cell zones of LNs in bone marrow 
chimeric Ccl17E/+Apoe-/- → Apoe-/- mice, suggesting that the CCL17+ DC subtype in the LN is 
continuously replaced by cells from the periphery homing to LNs, where the probability of 
encountering rare Ag-specific T cells might be higher than in plaques. It remains to be 
elucidated whether CCL17+ DCs or their precursors migrate via the lymph, as suggested by 
their expression of Ccr7, or are directly recruited via HEVs or take a detour via peripheral 
tissue. 
Finally, CCL17 has been shown to activate Ccr4-expressing platelets in mice. CCL17-
expressing DCs in the vascular wall might thus in addition be in prime position to initiate 
platelet activation contributing to atherosclerotic lesion formation (Huo, Schober et al. 2003; 
Gleissner, von Hundelshausen et al. 2008). 
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IV.5 T cells primed by CCL17+ DCs mediate atherogenesis 
Systemic changes in immune responses are crucial determinants of atherosclerotic plaque 
progression (Hansson 2005; Weber, Zernecke et al. 2008) and are controlled by different pro- 
and anti-inflammatory cytokines. Here we show that genetic deficiency in Ccl17 is associated 
with a significant reduction in atherosclerosis and a reduced Th1 cytokine bias in Apoe-/- 
mice. We observed decreased expression of the pro-inflammatory cytokine IFN-γ and also 
of IL-17, while levels of IL-4 and IL-10 were increased. Accordingly, Th1-mediated contact-
hypersensitivity responses were impaired and the survival of cardiac allografts was prolonged 
in the absence of CCL17 (Alferink, Lieberam et al. 2003). A reduction in atherosclerosis due 
to an impaired Th1 polarization is in line with findings that mice deficient in the Th1-
transcription factor T-bet display attenuated atherosclerosis (Buono, Binder et al. 2005), and 
with the pro-atherogenic role of Th1-driven IFN-γ and protective effects of a Th2-cell bias 
and Th2-related IL-10 in atherosclerosis (Mallat, Besnard et al. 1999; Binder, Hartvigsen et 
al. 2004; Kleemann, Zadelaar et al. 2008; Schulte, Sukhova et al. 2008). Furthermore, 
experiments in mice with a Th2 cell bias indicated that the Th2 cell response inhibits 
atherogenesis in hyperlipidemic mice (Schulte, Sukhova et al. 2008). Also Treg cells have 
been identified as powerful inhibitors of atherosclerosis and were shown to secrete IL-10 (Ait-
Oufella, Salomon et al. 2006). However, Foxp3 expression did not differ in LNs of Ccl17E/+ 
Apoe-/- and Ccl17E/E Apoe-/- mice, indicating that Treg cell differentiation is not influenced by 
CCL17 and that elevated IL-10 levels observed in Ccl17E/E Apoe-/- mice are likely due to a 
prevalence of a Th2 bias as a consequence of insufficient Th1 polarization or only weak TCR 
signals (Tao, Constant et al. 1997; Langenkamp, Messi et al. 2000). It has been shown that 
IL-4 injection decreased aortic lesion size in mice under conditions of mild 
hypercholesterolemia (Kleemann, Zadelaar et al. 2008). In our models, enhanced IL-4 
cytokine expression in Ccl17E/E Apoe-/- mice might in addition provide B cell help for IgG Ab 
production (Reiter and Pfeffer 2002). In line with a protection from atherosclerosis in Apoe-/- 
mice conferred by B cells and increased Ab titers to oxLDL (Caligiuri, Nicoletti et al. 2002) 
and extremely low levels of IgG1 Abs in IL-4-/- Apoe-/- mice compared to Apoe-/- mice 
(Davenport and Tipping 2003), increased titers of IgG Abs and specifically Th2-associated 
IgG1 Abs to modified LDL in Ccl17E/E Apoe-/- mice might in part contribute to the protection 
against atherosclerosis. Thus, in the absence of CCL17 in Apoe-/- mice, the interplay and net 
effect of different  
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cytokines and reciprocal Th cell populations limit lesion growth and progression of 
atherosclerosis. 
Little is yet known about the functions of IL-17 and a Th17 immune response in 
atherosclerosis. Our findings imply that IL-17 is associated with a pro-atherosclerotic 
phenotype. The identification of infiltrating IFN-γ/IL-17-expressing T cells in human 
atherosclerotic coronary arteries (Schulte, Sukhova et al. 2008) further supports the notion 
that not only Th1 cells but also Th17 cells or a population simultaneously secreting both IFN-
γ and IL-17 (Caligiuri, Nicoletti et al. 2002) might be important in atherosclerosis. Also 
interesting in this regard is, that IL-4 was shown to reduce the expression of IL-17, which on 
the other hand down-regulated the expression of CCL17 in DCs and in lungs upon Ag 
restimulation, and to reduce the production of IL-4 and IL-5 in regional LNs (Schnyder-
Candrian, Togbe et al. 2006). These data point to an important feed back loop of these 
pathways. 
Adoptive transfer of T cells determined that T cells have a net atherogenic effect in 
hyperlipemic mice (Zhou, Nicoletti et al. 2000), although the exact mechanisms remain to be 
elucidated. In line with these findings, adoptive transfer studies of CD4+ T cells from 
atherosclerotic Ccl17+/+ Apoe-/- but not Ccl17E/E Apoe-/- mice governed the development of 
atherosclerosis in recipient Apoe-/- mice, identifying the subpopulation of CCL17+ DCs as the 
central subpopulation in initiating T cell responses that not only precede but also determine 
atherosclerotic lesion development.  
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IV.6 Perspectives 
DCs have been found in atherosclerotic lesions, but their role in lesion development remains 
unclear. Here we show that deletion of CCL17, a chemokine expressed by DCs, leads to 
reduced atherosclerosis in hypercholesterolemic Apoe-/- mice. We also demonstrate that 
transfer of CD4+ T cells from Ccl17+/+ Apoe-/- but not from Ccl17E/E Apoe-/- mice increased 
lesion formation in this model. Furthermore, we observed that Ccl17E/E Apoe-/- mice have a 
preponderance of Th2 cytokines, in contrast with the Th1 and Th17 profile in Ccl17+/+  
Apoe-/- mice. The next goal would be to clarify, whether these effects on lesion progression 
are restricted to Ccl17-deficiency in DCs, or whether also CCL17-dependent effects in other 
cell types are involved. This could be done by injection of EGFP+ Ccl17E/+ and EGFP+ 
Ccl17E/E BMDCs into the tail vein of Apoe-/- recipient mice, followed by a high-fat diet 
feeding over 12 weeks. In addition, these BMDCs could be loaded with modified LDL prior 
to injection. Together, these experiments could clarify to which extent CCL17+ DCs account 
for the observed effects in atherosclerosis development and progression. 
Furthermore, we observed that DC-derived CCL17 is necessary for efficient T cell 
activation, priming and polarization, but it still needs to be elucidated, whether CCL17+ DC-
dependent T cell priming occurs mainly in the LN or within the vascular wall, or at both 
locations as shown for the presence of CCR4+ T cell-DC clusters in inflamed skin as well as 
in LNs (Katou, Ohtani et al. 2001). Therefore, it is well conceivable that peripheral CCL17+ 
DCs also attract CCR4+ effector and memory Th1 and Th2 cells to sites of lesion growth to 
initiate or maintain inflammation. To investigate this, labeled T cells could be injected into 
Ccl17E/+ Apoe-/- mice with advanced lesions, after which EGFP+ DC-T cell clusters could be 
searched for in LNs and plaques using immunofluorescence microscopy.  
Besides, CCL17+ DCs prime T cells in a Th1 and Th17 specific manner. It still remains 
unclear, whether the source of IFN-γ and IL-17 in this study comes from the same T cell or 
whether CCL17 triggers both Th1 and Th17 polarization. This could be investigated by using 
intracellular cytokine staining methods after T cell stimulation with recombinant CCL17 or 
blocking CCL17 Ab. In addition, the role of Th17 in atherosclerosis needs to be clarified 
using different knock-out mice models or blocking Ab treatments. 
Moreover, it is important to examine the signaling mechanisms and regulation of 
CCL17 via its receptor CCR4 and CCR8. The results of this study also need to be confirmed 
by using Ccr4-/- and Ccr8-/- mice. Adoptive transfer assays similar to those used in this study  
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using isolated CD4+ T cells from Ccr4-/- and Ccr8-/- mice, could be performed. In addition, 
intracellular cytokine staining could be done to clarify T cell polarization in Ccr4-/- and Ccr8-/- 
compared to wt T cells. 
Finally, our data establish for the first time that DC-specific effector functions mediated 
by CCL17 are crucially involved in the pathogenesis of atherosclerosis, which is known to be 
a chronic inflammation disease. Hence, DC-derived CCL17 may represent an attractive 
therapeutic target for the treatment of atherosclerosis and possibly also for other inflammation 
diseases (e.g. Crohn`s disease). To investigate this notion, the development and progression of 
atherosclerosis could be studied in Apoe-/- mice treated with a blocking CCL17 Ab, which 
could shed a light on the usefulness of CCL17 as a therapeutic target for the treatment of 
chronic inflammatory diseases. 
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V Summary 
V.1 Summary (English) 
In this study, the DC-derived chemokine CCL17 and its role in the pathogenesis of 
atherosclerosis was investigated. 
By using a ‘knock-in’ mice expressing a targeted replacement of the Ccl17 gene by 
eGFP, we observed that CCL17+ DCs belong to a mature subpopulation of cDCs related to 
the myeloid lineage. Microarray profiling showed no further difference in gene regulation or 
even intrinsic defects of EGFP+ Ccl17E/E compared with EGFP+ Ccl17E/+ BMDCs. 
Additionally, normal DC functions such as phagocytosis or migration were not altered in 
Ccl17 knock-out DCs.  
In vivo, a network of CD11c+ DCs could be detected in the intima of the vessel wall of 
naïve wt mice, but these cells did not express CCL17, in contrast to a prominent expression of 
MHC-II. However, during plaque development CCL17+ DCs accumulate within inflamed 
atherosclerotic lesions in Apoe-/- mice. In addition, CCL17+ DCs were detected in lesions of 
bone marrow transplanted mice, indicating that these DCs are recruited from the bone marrow 
to the site of inflammation. Furthermore, we demonstrated that CCL17-deficiency reduces 
atherosclerotic plaque formation with a decreased macrophage content in the plaque, while 
the content of SMCs was increased, indicating a more stable plaque phenotype compared to 
the phenotype observed in Ccl17+/+ Apoe-/- mice. 
In line with the findings that CCL17 attracts T cells, we observed that CCL17+ DCs 
attract CD4+ T cells in vitro and in vivo. In addition, increased numbers of CD3+ T cells were 
detected in atherosclerotic plaques of Ccl17+/+ Apoe-/- compared with Ccl17E/E Apoe-/- mice. 
Furthermore, CCL17 seems to be necessary for efficient T cell activation, as higher IL-2 
levels were observed in the supernatants of T cells cocultured with CCL17+ BMDCs. 
Moreover IFN-γ levels were significantly higher in those cultures, indicating that T cells were 
primed and polarized in a Th1 specific manner. The difference in cytokine profile was also 
observed in vivo. In LNs of Ccl17+/+ Apoe-/- mice, Ifn-γ and Il-17 transcription levels were up-
regulated, while the typical Th2 cytokines Il-4 and Il-10 were down-regulated in comparison 
to Ccl17E/E Apoe-/- mice. 
Finally, adoptive transfer experiments demonstrated that T cells isolated from Ccl17E/E 
Apoe-/- mice and injected into Apoe-/- recipient mice act atheroprotective. Lesion development 
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in these animals was significantly reduced when compared with Apoe-/- mice receiving T cells 
from Ccl17+/+ Apoe-/-. These data open the possibility of achieving therapeutic regression and 
stabilization of advanced atherosclerotic lesions by targeting CCL17. 
V.2 Zusammenfassung 
In dieser Arbeit wurde die Rolle von Dendritischen Zellen und ihrem Chemokin TARC 
hinsichtlich der Pathogenese der Arterosklerose untersucht. 
Mit Hilfe einer knock-in Maus, die anstatt des Ccl17 Gens ein eGFP trägt, konnte 
festgestellt werden, dass CCL17+ Dendritische Zellen zur Klasse reifer cDCs myeloiden 
Ursprungs gehören. Microarray-Analysen zeigten keine weiteren Unterschiede in der 
Genregulation oder gar intrinsische Defekte von EGFP+ Ccl17E/E im Vergleich mit EGFP+ 
Ccl17E/+ BMDCs. Desweiteren übt der Ccl17 knock-out in DCs keine Auswirkungen auf 
typische DC-Funktionen wie Phagocytose oder Migration aus.  
In vivo konnte ein Netzwerk von CD11c+ DCs in der Intima der Gefäßwände gesunder 
wt Mäuse detektiert werden. Diese vaskulären DCs exprimieren kein CCL17, sind aber 
positiv für MHC-II. Während der Plaqueentwicklung jedoch akkumulieren CCL17+ DCs in 
den Entzündungsherden atherosklerotischer Läsionen in Apoe-/- Mäusen. Zusätzlich konnten 
CCL17+ DCs in den Läsionen von Mäusen detektiert werden, die mit Knochenmark 
transplantiert wurden. Dieser Befund deutet darauf hin, dass diese DCs vom Knochenmark 
zum Entzündungsherd rekrutiert werden. Wir konnten zeigen, dass der Verlust von CCL17 
eine Reduktion der atherosklerotischen Plaqueentstehung bewirkt. Gleichzeitig findet man 
weniger Makrophagen im Plaque, während die Anzahl an glatten Muskelzellen zunimmt. Dies 
deutet auf einen stabileren Plaquephänotyp hin im Vergleich zu Ccl17+/+ Apoe-/- Mäusen. 
Im Einklang mit den Befunden, dass CCL17 T Zellen anlockt, konnten wir beobachten, 
dass CCL17+ DCs CD4+ T Zellen sowohl in vitro als auch in vivo anlocken. Zusätzlich zu 
diesen Ergebnissen konnten weniger CD3+ T Zellen in atherosklerotischen Läsionen von 
Ccl17+/+ Apoe-/- im Vergleich zu Ccl17E/E Apoe-/- Mäusen detektiert werden. Desweiteren 
scheint CCL17 für eine effiziente T-Zell-Aktivierung notwendig zu sein. Hinweise hierfür 
ergaben Analysen des Überstands hinsichtlich des IL-2-Levels von T-Zell/CCL17+ BMDC-
Kokulturen. Darüber hinaus war der IFN-γ Level in diesen Kulturen significant erhöht, was 
darauf hindeutet, dass T Zellen in Richtung Th1 geprimt und polarisiert werden. Dieser 
Unterschied im Zytokinprofil konnte auch in vivo beobachtet werden. In den Lymphknoten 
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von Ccl17+/+ Apoe-/- Mäusen, waren die Transkriptionslevel für Ifn-γ and Il-17 hochreguliert, 
während typische Th2 Zytokine wie Il-4 and Il-10 runterreguliert werden im Vergleich zu 
Ccl17E/E Apoe-/- Mäusen. 
Schlussendlich zeigten adoptive Transferexperimente, dass T Zellen isoliert aus 
Ccl17E/E Apoe-/- Mäusen und injeziert in Apoe-/- Empfängermäuse atheroprotektiv wirken. Die 
Läsionsentwicklung in diesen Tieren war signifikant reduziert im Vergleich mit Apoe-/- 
Mäusen, die T Zellen aus Ccl17+/+ Apoe-/- Mäusen empfangen haben. Zusammenfassend 
eröffnen diese Daten die Möglichkeit eines therapeutischen Ansatzes im Hinblick auf die 
Stabilisierung fortgeschrittener atherosklerotischen Läsionen durch CCL17 targeting. 
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